<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2021.718213</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in <italic>Pseudomonas aeruginosa</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fraser-Pitt</surname>
<given-names>Douglas J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/562917"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dolan</surname>
<given-names>Stephen K.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1357120"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toledo-Aparicio</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1399244"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hunt</surname>
<given-names>Jessica G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1399232"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Daniel W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lacy-Roberts</surname>
<given-names>Niamh</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nupe Hewage</surname>
<given-names>Piumi Sara</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1359944"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stoyanova</surname>
<given-names>Teodora N.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manson</surname>
<given-names>Erin</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McClean</surname>
<given-names>Kevin</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1399258"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inglis</surname>
<given-names>Neil F.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mercer</surname>
<given-names>Derry K.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/707284"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O&#x2019;Neil</surname>
<given-names>Deborah A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>NovaBiotics Ltd</institution>, <addr-line>Aberdeen</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Biochemistry, University of Cambridge</institution>, <addr-line>Cambridge</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>SNIPR Biome, University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>School of Pharmacy and Life Sciences, Robert Gordon University</institution>, <addr-line>Aberdeen</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>College of Medical, Veterinary &amp; Life Sciences, University of Glasgow</institution>, <addr-line>Glasgow</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Proteomics Facility Services, Moredun Research Institute</institution>, <addr-line>Penicuik</addr-line>, <country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ruggero La Rosa, Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain), Denmark</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Erin Samantha Gloag, The Ohio State University, United States; Volker Behrends, University of Roehampton London, United Kingdom</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Douglas J. Fraser-Pitt, <email xlink:href="mailto:doug@novabiotics.co.uk">doug@novabiotics.co.uk</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Bacterial Pathogenesis, a section of the journal Frontiers in Cellular and Infection Microbiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>11</volume>
<elocation-id>718213</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>05</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>08</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Fraser-Pitt, Dolan, Toledo-Aparicio, Hunt, Smith, Lacy-Roberts, Nupe Hewage, Stoyanova, Manson, McClean, Inglis, Mercer and O&#x2019;Neil</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Fraser-Pitt, Dolan, Toledo-Aparicio, Hunt, Smith, Lacy-Roberts, Nupe Hewage, Stoyanova, Manson, McClean, Inglis, Mercer and O&#x2019;Neil</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<italic>Pseudomonas aeruginosa</italic> is a major opportunistic human pathogen which employs a myriad of virulence factors. In people with cystic fibrosis (CF) <italic>P. aeruginosa</italic> frequently colonises the lungs and becomes a chronic infection that evolves to become less virulent over time, but often adapts to favour persistence in the host with alginate-producing mucoid, slow-growing, and antibiotic resistant phenotypes emerging. Cysteamine is an endogenous aminothiol which has been shown to prevent biofilm formation, reduce phenazine production, and potentiate antibiotic activity against <italic>P. aeruginosa</italic>, and has been investigated in clinical trials as an adjunct therapy for pulmonary exacerbations of CF.&#xa0;Here we demonstrate (for the first time in a prokaryote) that cysteamine prevents glycine utilisation by <italic>P. aeruginosa</italic> in common with previously reported activity blocking the glycine cleavage system in human cells. Despite the clear inhibition of glycine metabolism, cysteamine also inhibits hydrogen cyanide (HCN) production by <italic>P. aeruginosa</italic>, suggesting a direct interference in the regulation of virulence factor synthesis. Cysteamine impaired chemotaxis, lowered pyocyanin, pyoverdine and exopolysaccharide production, and reduced the toxicity of <italic>P. aeruginosa</italic> secreted factors in a <italic>Galleria mellonella</italic> infection model. Thus, cysteamine has additional potent anti-virulence properties targeting <italic>P. aeruginosa</italic>, further supporting its therapeutic potential in CF and other infections.</p>
</abstract>
<kwd-group>
<kwd>virulence</kwd>
<kwd>biofilm</kwd>
<kwd>
<italic>Pseudomonas aeruginosa</italic>
</kwd>
<kwd>novel therapeutic</kwd>
<kwd>glycine cleavage complex</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="112"/>
<page-count count="18"/>
<word-count count="10175"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>
<italic>Pseudomonas aeruginosa</italic> is a versatile and opportunistic human pathogen and often recalcitrant to antibiotic therapy. It is a major cause of ventilator-associated pneumonia (VAP) in hospitals (<xref ref-type="bibr" rid="B51">Koulenti et&#xa0;al., 2009</xref>), a less common cause of community acquired pneumonia (CAP) and can also cause infections at other body sites such as wound infections, urinary tract catheter-associated infections and gangrenous diabetic foot ulcer, (<xref ref-type="bibr" rid="B34">Gj&#xf8;dsbol et&#xa0;al., 2006</xref>; <xref ref-type="bibr" rid="B68">Nathwani et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B98">Trubiano and Padiglione, 2015</xref>; <xref ref-type="bibr" rid="B48">Kim et&#xa0;al., 2020</xref>). Acute <italic>P. aeruginosa</italic> pneumonia can occur in immunocompetent patients but susceptible and immunocompromised patients such as those receiving mechanical ventilation, or the very young and old are most at risk. Cystic fibrosis (CF) patients have dysfunctional mucocilliary clearance due to thick, dehydrated mucus, and are at risk of lung colonisation by <italic>P. aeruginosa.</italic> Despite recent falls in prevalence, it is still a common species found in the sputum of adults with CF (<xref ref-type="bibr" rid="B15">Cystic Fibrosis Foundation Patient Registry: 2018 Annual Data Report, 2019</xref>). This Gram negative motile rod-shaped bacterium was thought to be intrinsically resistant to macrolide antibiotics, though recent evidence suggests that the high minimal inhibitory concentrations (MICs) found in <italic>in vitro</italic> susceptibility testing media were less reflective of antimicrobial activity in physiological conditions (<xref ref-type="bibr" rid="B9">Buyck et&#xa0;al., 2012</xref>). Nevertheless, the rising incidence of acquired resistance, particularly to carbapenems has led to its designation as a critical priority pathogen of concern by WHO (<xref ref-type="bibr" rid="B104">World Health Organisation (WHO), 2017</xref>).</p>
<p>
<italic>P. aeruginosa</italic> can produce a wide array of virulence factors, such as phenazine pigments, as well as cytotoxins, exotoxins, elastase, phospholipase C, and protease A (<xref ref-type="bibr" rid="B4">Azam and Khan, 2019</xref>). In CF, opportunistic isolates sometimes establish chronic infection which can be very difficult to eradicate (<xref ref-type="bibr" rid="B60">Lyczak et&#xa0;al., 2000</xref>; <xref ref-type="bibr" rid="B31">Gibson et&#xa0;al., 2003</xref>). During early infection <italic>P. aeruginosa</italic> isolates are usually highly motile, express type III secretion system effector molecules and the LPS O antigen. Adaptation to chronic infection, often seen within the airways of adults with CF, leads toward a mucoid phenotype, alginate production, acquisition of antibiotic resistance and loss of motility (<xref ref-type="bibr" rid="B91">Smith et&#xa0;al., 2006</xref>; <xref ref-type="bibr" rid="B66">Mowat et al., 2011</xref>). Evolutionary divergence and adaptation to certain microenvironments can even take place within specific parts of the CF lung (<xref ref-type="bibr" rid="B107">Winstanley et&#xa0;al., 2016</xref>). The volatile, and highly toxic compound HCN can be detected in the breath of people with CF colonised with <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B32">Gilchrist et al., 2013</xref>; <xref ref-type="bibr" rid="B33">Gilchrist et&#xa0;al., 2015</xref>) and its presence in sputum significantly correlates with poorer lung function in individuals with CF and non-CF bronchiectasis (<xref ref-type="bibr" rid="B84">Ryall et&#xa0;al., 2008</xref>). Over time, <italic>P. aeruginosa</italic> colonisation is associated with damage to the lung architecture and declining lung function in CF (<xref ref-type="bibr" rid="B47">Kerem et&#xa0;al., 2014</xref>). Most of the virulence traits of <italic>P. aeruginosa</italic> are secreted factors under the control of complex, overlapping quorum sensing systems which include those regulated by LasR, RhlR, and MvfR (PqsR) transcriptional regulators. Although these systems have been described as hierarchical (with LasR system at the top) and interdependent (<xref ref-type="bibr" rid="B75">Pesci et&#xa0;al., 1999</xref>; <xref ref-type="bibr" rid="B61">McGrath et&#xa0;al., 2004</xref>; <xref ref-type="bibr" rid="B37">Heeb et al., 2011</xref>), LasR loss of function mutations often arise in chronic CF infections and both RhlR and PQS can function independently (<xref ref-type="bibr" rid="B50">Kostylev et&#xa0;al., 2019</xref>).</p>
<p>Cysteamine is a simple aminothiol, produced endogenously through the action of pantetheinases such as vanin-1 in the metabolism of co-enzyme A (<xref ref-type="bibr" rid="B78">Pitari et&#xa0;al., 2000</xref>) and is a molecule which may have an underappreciated role in immunity to infection (<xref ref-type="bibr" rid="B26">Fraser-Pitt and Mercer, 2021</xref>). It is also a therapeutic licensed for many years for the treatment of the lysosomal storage disorder, cystinosis (<xref ref-type="bibr" rid="B86">Schneider et&#xa0;al., 1995</xref>). Cysteamine may also have therapeutic potential as both an oral adjunct to standard of care therapy (SOCT) during infectious exacerbations in CF and as an inhaled maintenance therapy adjunct to antimicrobial therapy. It potentiates antibiotic activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="B12">Charrier et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B19">Devereux et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B27">Fraser-Pitt et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>), as well as in murine models of infection (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>). Oral cysteamine bitartrate, adjunct to SOCT, resulted in statistically significant improvements in patient reported outcome measures and biomarkers of inflammation and infection including reduced white blood cell count, and CRP in patients experiencing an infectious pulmonary exacerbation (<xref ref-type="bibr" rid="B20">Devereux et&#xa0;al., 2020</xref>). Cysteamine may also stimulate autophagy, and reduce proteostasis, and some groups have shown that this increases trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) to the plasma membrane (<xref ref-type="bibr" rid="B18">De Stefano et&#xa0;al., 2014</xref>), although other groups have questioned this (<xref ref-type="bibr" rid="B3">Armirotti et&#xa0;al., 2019</xref>). Cysteamine has been demonstrated to improve the clearance of intracellular pathogens including <italic>P. aeruginosa</italic> and <italic>Burkholderia cenocepacia</italic> from CF macrophages (<xref ref-type="bibr" rid="B24">Ferrari et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B89">Shrestha et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B90">Shrestha et&#xa0;al., 2020</xref>). Cystic fibrosis has recently seen a paradigm shift in terms of care with the introduction of combinatorial modulator therapies which address the underlying cause of the condition (<xref ref-type="bibr" rid="B64">Middleton et&#xa0;al., 2019</xref>). Nonetheless, infectious exacerbations and infection remain as major challenges in CF clinical care and there is still a critical need for novel and effective interventions that target CF symptomology. The broad-spectrum antibiotic potentiation, mucolytic activities, and anti-inflammatory properties of cysteamine may be of benefit to all CF genotypes.</p>
<p>Cysteamine interferes with the REDOX balance of the bacterial cell through conversion to the disulphide cystamine, which depletes intracellular NADPH and cellular reducing power. It can also disrupt the metabolism of <italic>P. aeruginosa</italic>, and it was noted that sub-lethal concentrations of cysteamine could sensitise it to other antimicrobial agents. Cysteamine has a marked effect on pigment production in numerous strains, and the export of pyomelanin from <italic>B. cenocepacia</italic> (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>). Cysteamine is a highly reactive small molecule, so the precise bacterial cell target (or more likely, targets) that are responsible for such pleiotropic activity remain to be elucidated. As <italic>P. aeruginosa</italic> is a versatile pathogen with a highly flexible metabolism (<xref ref-type="bibr" rid="B21">Dolan et&#xa0;al., 2020</xref>), extensive metabolic redundancy can hinder the identification of the precise target of antimicrobials used against this organism. Here we explored further the mechanisms of cysteamine-mediated interference in bacterial metabolism and undermining of virulence traits of <italic>P. aeruginosa.</italic>
</p>
<p>Cysteamine has long been known to inhibit the glycine cleavage system found in the mitochondria of eukaryotic cells (<xref ref-type="bibr" rid="B111">Yudkoff et&#xa0;al., 1981</xref>) through inhibition of the glycine cleavage system found in the mitochondria (<xref ref-type="bibr" rid="B35">Hayasaka and Tada, 1983</xref>). This multienzyme system has a role in glycine and serine catabolism as well as the provision of methyl groups during the biosynthesis of methionine and purines. In mammals the system includes the P-protein, H-protein, L-protein and T-protein - the H-protein is one of the very few lipoylated proteins and the P-protein requires the pyridoxal phosphate (PLP) cofactor. The system is widely evolutionarily conserved in mammalian, plant and many bacterial species. The glycine decarboxylase enzyme is exquisitely sensitive to competitive inhibition by cysteamine with a Ki of 5 &#xb5;M, which is thought to act <italic>via</italic> interaction with PLP (<xref ref-type="bibr" rid="B58">Lowry et&#xa0;al., 1986</xref>). Cysteamine (in common with some other aminothiols) has long been known to react with PLP (<xref ref-type="bibr" rid="B7">Buell and Hansen, 1960</xref>) by forming thiazolidine ring. It is known to interfere with PLP-dependent enzyme kinetics (<xref ref-type="bibr" rid="B17">De Marco et&#xa0;al., 1965</xref>), and as an endogenous molecule there has been speculation as to the biological role (<xref ref-type="bibr" rid="B97">Terzouli et&#xa0;al., 1998</xref>). <italic>P. aeruginosa</italic> possesses two copies of glycine dehydrogenase (decarboxylating) genes, <italic>gcvP1</italic> and <italic>gcvP2</italic>. The GcvP1 and GcvP2 proteins of <italic>P. aeruginosa</italic> are also PLP-dependent enzymes and GcvP2 belongs to the <italic>gcs2</italic> cluster required for glycine catabolism (<xref ref-type="bibr" rid="B59">Lundgren et&#xa0;al., 2013</xref>). Glycine is the precursor for HCN production, first demonstrated in <italic>P. fluorescens</italic> (<xref ref-type="bibr" rid="B54">Laville et&#xa0;al., 1998</xref>), and the glycine cleavage system has been implicated in HCN production in <italic>P. aeruginosa</italic> too (<xref ref-type="bibr" rid="B85">Sarwar et&#xa0;al., 2016</xref>). Inhibition of glycine catabolism caused by increases in ammonia (a product of the reaction) has been reported to increase the abundance of the glycine substrate which in turn raises the amount utilised to make HCN <italic>via</italic> the gene cluster <italic>hcnABC</italic> (<xref ref-type="bibr" rid="B109">Yan et&#xa0;al., 2018</xref>).</p>
<p>Here, we demonstrate that cysteamine inhibits glycine utilisation by <italic>P. aeruginosa</italic>, and that the glycine cleavage system has unexpected inhibitory activity on HCN production. We also show for the first time that cysteamine disrupts chemotaxis and swarming motility which may be linked to disruption of metabolism, but the glycine cleavage system is not the only target. One of the most striking impacts of cysteamine treatment on <italic>P. aeruginosa</italic> is the inhibition of pigment production. <italic>Pseudomonas</italic> sp. produce a wide array of pigments, including pyocyanin, a blue REDOX active compound and toxic virulence factor. We have reported qualitative observations on cysteamine-mediated changes in pigment production on a wide range of <italic>P. aeruginosa</italic> strains previously (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>) and here we quantify the effects on pyocyanin. <italic>P. aeruginosa</italic> also secretes the fluorescent green-yellow iron-chelating siderophore, pyoverdine. Pyoverdine is necessary for virulence in numerous infection models and chemical inhibitors of the production of this siderophore have demonstrated potential in mouse models of infection (<xref ref-type="bibr" rid="B45">Kang et&#xa0;al., 2019</xref>) therefore we also investigated the impact of cysteamine on pyoverdine fluorescence. Whilst inhibition of biofilm formation by cysteamine has been demonstrated previously against a wide range of bacteria (<xref ref-type="bibr" rid="B12">Charrier et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B27">Fraser-Pitt et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al,. 2018</xref>), here we demonstrate that it can reduce exopolysaccharide production in an alginate-producing strain and inhibits the induction of biofilm formation by the aminoglycoside, tobramycin. These data illustrate that cysteamine can dysregulate multiple aspects of <italic>P. aeruginosa</italic> virulence.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>Unless otherwise stated, chemicals, reagents and media were purchased from Sigma-Aldrich (MO, USA).</p>
<sec id="s2_1">
<title>Bacterial Strains, Growth Media and Culture Conditions</title>
<p>
<italic>P. aeruginosa</italic> PAO1 a commonly used type strain (<xref ref-type="bibr" rid="B41">Holloway, 1955</xref>) was purchased from the American Type Culture Collection. PA14 (UCBPP-PA14) is a clinical burns isolate (<xref ref-type="bibr" rid="B81">Rahme et&#xa0;al., 1995</xref>) first sequenced in 2004 (<xref ref-type="bibr" rid="B36">He et&#xa0;al., 2004</xref>) and representative of common clonal isolates found worldwide in numerous disease states including CF (<xref ref-type="bibr" rid="B105">Wiehlmann et&#xa0;al., 2007</xref>). NH57388A is a stable <italic>mucA</italic> mucoid isolate derived from CF sputum which produces pyocyanin (<xref ref-type="bibr" rid="B70">Norman et&#xa0;al., 2016</xref>) and NH57388B is a non-mucoid quorum-sensing deficient strain that does not produce N-acylhomoserine lactone signalling molecules (<xref ref-type="bibr" rid="B40">Hoffmann et&#xa0;al., 2005</xref>).</p>
<p>The &#x394;<italic>gcvP2</italic> PAO1 mutant was created by PCR amplifying flanking regions 800-1000 bp upstream and downstream of the <italic>gcvP2</italic> ORF. Upstream and downstream regions were then overlapped and cloned into the suicide vector pEX19Gm using Gibson assembly as described previously (<xref ref-type="bibr" rid="B42">Huang and Wilks, 2017</xref>). The resulting deletion plasmid was then transformed into <italic>P. aeruginosa</italic> PAO1 by electroporation and selected for on LB plates containing 50 &#xb5;g/ml gentamycin. Deletion mutants were identified <italic>via sacB</italic> mediated sucrose counter-selection and confirmed by PCR. Primers used are described in <xref ref-type="supplementary-material" rid="ST1">
<bold>Table S1</bold>
</xref>.</p>
<p>Growth media included cation-adjusted M&#xfc;ller-Hinton broth 2 (MHB). M9 minimal media was prepared (<xref ref-type="bibr" rid="B65">Miller, 1972</xref>) with 20 mM carbon sources as described previously (<xref ref-type="bibr" rid="B85">Sarwar et&#xa0;al., 2016</xref>). Growth was assessed by optical density (O.D.) of 100 &#xb5;l volumes at 625 nm over time at 37&#xb0;C in 96-well flat-bottomed plates (Thermo-Fisher, MA, USA) using a Synergy (Biotek, VT, USA) plate reader. When not in routine use strains were cryopreserved in 20% glycerol (80% M&#xfc;ller-Hinton broth) at -80&#xb0;C for long term storage.</p>
</sec>
<sec id="s2_2">
<title>Susceptibility (MIC) and Chemotaxis Experiments</title>
<p>The MIC (minimum inhibitory concentration at which 100% of bacterial growth is prevented) of cysteamine in different media was calculated as described using the CLSI broth microdilution procedure M07-A10 (<xref ref-type="bibr" rid="B102">Wayne, 2015</xref>). The standard solid media used to maintain strains was M&#xfc;ller-Hinton agar (MHA) containing 1.5% granulated agar (Melford Laboratories, UK), Chemotaxis swimming and swarming assessments were performed on M9 minimal media containing 0.3% granulated agar, and 20 mM glucose, or 0.2% w/v casamino acids +/- cysteamine at 200 mg/L in 2-compartment plates. Overnight cultures grown in MHB were pelleted, washed and resuspended in M9 minimal salts to achieve uniform OD600 = 0.4 &#xb1; 0.02 and 2 &#xb5;l volumes were spotted onto the plate surface in a sterile class II containment hood prior to incubation at 37&#xb0;C (<xref ref-type="bibr" rid="B74">Parales and Ditty, 2018</xref>). Images were captured at 24 and 48 h using a Nikon D5100 (Japan) at the same conditions and settings (f/5.3, 1/50 s, ISO-1600) and a Samsung Galaxy S20 (Samsung, South Korea) for colour images to demonstrate inhibition in pigment production. Colony area was calculated from colony radii. The experiment was conducted on three occasions.</p>
</sec>
<sec id="s2_3">
<title>Determination of Glycine in Culture Supernatants and Bacterial Cell Lysates</title>
<p>Bacterial cultures were prepared in M&#xfc;ller Hinton broth of each strain (PAO1 parent, and &#x394;<italic>gcvP2</italic> strain) using standardised inoculums of 1 in 150 dilution of 0.5 McFarland standard from overnight cultures. Three 10 ml cultures of each strain were used as controls (no exposure to cysteamine) and 3 cultures were treated with 200 mg/L cysteamine. After 24 h at 37&#xb0;C aliquots of bacterial cultures were serially diluted to determine final cfu/ml and then pelleted at 5,000 g for 5 min. Clarified supernatants were carefully removed without disturbing the pellets and filter sterilised using syringe-driven 0.22 &#xb5;M PES filter and stored at -80&#xb0;C prior to analysis. Bacterial pellets were washed 1 x in ice-cold PBS and centrifuged again before being resuspended in 1 ml sterile distilled water and transferred to a heating block and heated at 90&#xb0;C to lyse bacteria. Lysates were also stored at -80&#xb0;C prior to analysis. Glycine concentrations were determined fluorometrically using a glycine assay kit ab211000 (Abcam, Cambridge UK) according to the manufacturer&#x2019;s instructions on a black-walled 96-well microtitre plate and read using Biotek Synergy plate-reader (Biotek, VT, USA). Uninoculated M&#xfc;ller-Hinton broth (both treated and untreated) were used as controls and the addition of cysteamine did not affect the assay or the concentration of glycine in the media which was 2871.42 &#xb1;121.63 ng/ml (standard deviation).</p>
</sec>
<sec id="s2_4">
<title>Qualitative Hydrogen Cyanide Detection</title>
<p>Volatile HCN production was determined qualitatively <italic>via</italic> colorimetric detection using Whatman ashless 125 mm diameter filter paper discs (Whatman, UK) cut to fit above the surface of a two-compartment culture dish and impregnated with a solution containing 5 mg of copper (II) ethylacetoacetate and 5&#xa0;mg 4,4&#x2019;methylenebis-(N,N-dimethylaniline) in chloroform (<xref ref-type="bibr" rid="B10">Castric and Castric, 1983</xref>). Discs were left to dry and stored at 4&#xb0;C before use. Bacterial lawns were prepared from overnight cultures resuspended to a uniform 0.5 McFarland cell density and seeded onto two-compartment plates containing MHA or MHA with 200 mg/L cysteamine and allowed to dry in a class II containment hood. HCN detection discs were overlain above both compartments and sterile modified microfuge tube lids were used to keep the discs from touching the culture surface and to prevent condensation on the lids. Plates were incubated upright at 37&#xb0;C. PAO1, and &#x394;<italic>gcvP2</italic> PAO1 cultures tended to produce HCN quicker and were examined 18 h post inoculation, whereas PA14, and NH57388A and B were examined at 24 h. Experiments were conducted on three occasions.</p>
</sec>
<sec id="s2_5">
<title>
<italic>C. elegans</italic> Assessment of HCN Mediated Paralysis</title>
<p>
<italic>C. elegans</italic> was maintained under standard conditions (<xref ref-type="bibr" rid="B108">Wood, 1988</xref>). Worms were synchronised to achieve a population of young adults using the bleaching method described by Stiernagle (<xref ref-type="bibr" rid="B94">Stiernagle, 2006</xref>).</p>
<p>Bacteria were grown overnight on MHA, cultures were then diluted 1:100 in MHA and spread onto new MHA plates with or without the incorporation of cysteamine at the sub-inhibitory concentrations indicated in the agar and cultured for a further 24 h at 37&#xb0;C. Bacterial lawns were overlain with nitrocellulose membranes in a method adapted from Darby (<xref ref-type="bibr" rid="B16">Darby et&#xa0;al., 1999</xref>). Synchronized worms were then transferred to the nitrocellulose membrane and incubated at room temperature for 6 h. Worms were carefully lifted from the hydrophobic nitrocellulose membrane by 100 &#xb5;l M9 buffer and transferred to optically clear 96-well flat-bottomed plates to be examined for paralysis and scored for survival every hour, for 6 hours, by inspection under an Axiovert 40 CFL Microscope (Zeiss, Germany) at x 100 magnification. Worm paralysis was defined as no movement after mechanical stimulation.</p>
</sec>
<sec id="s2_6">
<title>Quantification of Pyocyanin</title>
<p>Pyocyanin was extracted from 12 ml <italic>P. aeruginosa</italic> cultures grown statically in MHB for 24 hours at 37&#xb0;C following inoculation with standardised 1:150 dilutions (80 &#xb5;l) of 0.5 McFarland suspensions of bacterial cells +/- cysteamine at stated concentrations. Following incubation bacterial cells were removed by centrifugation at 5,000 g for 5 min. Supernatants were then transferred to a fresh tube and further clarified by passing through a 0.22 &#xb5;M PES filter. Pyocyanin was extracted <italic>via</italic> liquid phase partitioning first with chloroform and then again with 0.2 N HCl and quantified by measuring the absorbance of 100 &#xb5;l volumes on 96-well flat-bottomed plates at 520 nm using a Synergy plate reader, concentrations were calculated using the extinction coefficient&#x2009;17.072 (<xref ref-type="bibr" rid="B52">Kurachi, 1958</xref>; <xref ref-type="bibr" rid="B23">Essar et&#xa0;al., 1990</xref>).</p>
</sec>
<sec id="s2_7">
<title>Quantification of Exopolysaccharide Production</title>
<p>The effect of cysteamine on the production of exopolysaccharide by the stable mucoid <italic>P. aeruginosa</italic> NH57388A was compared with the non-mucoid AHL-deficient NH57388B strain. Exopolysaccharide production was determined in a method adapted from that devised by <xref ref-type="bibr" rid="B82">Ramus (1977)</xref>. Each 12 ml culture was inoculated with standardised 1:150 dilutions (80 &#xb5;l) of 0.5 McFarland suspensions of bacterial cells from overnight cultures on MHA plates and cysteamine was added to final concentrations of 2 - 200 mg/L. Cultures were incubated statically for 120 h at 37&#xb0;C. Following incubation bacterial cells were removed by centrifugation at 5,000 g for 5 min at 4&#xb0;C, 1 ml volumes were transferred to sterile microfuge tubes and 100 &#xb5;l of acidified Alcian blue (1 mg/ml) was added which precipitates polyanionic exopolysaccharides such as alginate. Tubes were briefly vortexed (10 sec) to mix before further centrifugation at 5,000 g for 5 min at 4&#xb0;C which pellets the precipitate. Aliquots of supernatant (100 &#xb5;l) were then transferred to clear 96-well flat-bottomed plate and absorbance recorded at 610 nm using a Synergy plate reader. EPS concentration is inversely proportionate to absorbance of the unbound dye, and samples were quantified by comparison to a standard curve prepared using known concentrations of sodium alginate.</p>
</sec>
<sec id="s2_8">
<title>Biofilm Assay</title>
<p>Attachment of <italic>P. aeruginosa</italic> Pa14 biomass to 6-well plates was&#xa0;measured using an adapted crystal violet biofilm assay (<xref ref-type="bibr" rid="B73">O&#x2019;Toole&#xa0;et&#xa0;al., 1999</xref>) using standardised inoculum and MHB&#xa0;growth media &#xb1; cysteamine and/or tobramycin as&#xa0;described in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>. Planktonic growth in culture supernatants was measured after 24 h at 37&#xb0;C by transferring 100 &#xb5;l of each replicate to optically clear microtitre plates and recording absorbance at 625 nm. Crystal violet was released from washed surface-attached cells using 100% ethanol and 100 &#xb5;l of each replicate transferred to microtitre plates quantified at 595 nm.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Cysteamine and cystamine do not inhibit growth of planktonic cells <bold>(A)</bold> at 2 mg/L. Whilst sub-lethal concentrations of tobramycin (TOBI) reduced the number of planktonic cells at 24 h <bold>(A)</bold> induced biofilm formation over the same time period <bold>(B)</bold> and this is significantly reduced by adjunct treatment with cysteamine but not the disulfide, cystamine (n=9). ****p &#x2264; 0.0001 one-way ANOVA followed by Dunnet&#x2019;s <italic>post-hoc</italic> analysis. ns, not significant. *p is less than or equal to 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g004.tif"/>
</fig>
</sec>
<sec id="s2_9">
<title>Fractionation of <italic>P. aeruginosa</italic> Whole Cell Proteome Liquid Chromatography and Electrospray Ionisation Tandem Mass Spectrometry (LC-ESI-MS/MS) Analysis</title>
<sec id="s2_9_1">
<title>Sample Preparation and Separation by SDS PAGE</title>
<p>Six separate 10 ml cultures of <italic>P. aeruginosa</italic> PAO1 in MHB were prepared in sterile Universal tubes using single colonies grown from frozen stock revived overnight on MHA plates. Cultures were incubated statically for 20 hours and diluted in fresh media if necessary, to achieve growing cultures with an optical density of 0.3 at 625 nm. Each culture was then sub-cultured 1 ml into 9 ml of fresh MHB and incubated for 4 hours at 37&#xb0;C to achieve mid-logarithmic growth. Bacterial cells were pelleted by centrifugation at 5,000 g for 5 min. Following this, three of these cultures were resuspended in MHB media alone and three were resuspended in media containing sub-inhibitory 250 mg/L cysteamine and all cultures were incubated for a further 4 hours at 37&#xb0;C. Bacterial cells were then pelleted by centrifugation at 5,000 g for 5 min at 4&#xb0;C and washed once with ice cold PBS. Bacterial cell pellets were resuspended and lysed in 200 &#xb5;l of BugBuster (Merck Millipore, MA, USA) containing a protease inhibitor cocktail (Complete Mini, Roche Diagnostics GmbH, Basel, Switzerland) at the manufacturer&#x2019;s recommended concentration. Lysate protein concentrations were determined by bicinchoninic acid (BCA) assay (<xref ref-type="bibr" rid="B92">Smith et&#xa0;al., 1985</xref>) and equal amounts 5 mg total protein of whole cell lysates were separated by one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a precast 4-20% gradient Tris-glycine gel. Gel was visualised with Coomassie based EZBlue (Sigma, MO, USA) stain.</p>
</sec>
<sec id="s2_9_2">
<title>LC-ESI-MS/MS Analysis</title>
<p>Each of 6 lanes of whole cell proteins was fractionated into 21 slices. Each slice was subjected to in-gel tryptic digestion, reduction, alkylation and trypsinolysis, followed by reversed-phase liquid chromatographic separation of tryptic peptides using rapid monolithic column chromatography and ESI-MS/MS using a fast-scanning three-dimensional ion trap tandem mass spectrometer (Bruker Daltonics amaZon-ETD).</p>
<p>LC was performed using an Ultimate 3000 nano-HPLC system (Dionex, LC-Packings) using the method described previously (<xref ref-type="bibr" rid="B8">Burgess et&#xa0;al., 2009</xref>).</p>
<p>Mass spectrum peak lists for peptides and fragmentation ions were compared with <italic>in-silico</italic> published sequence for <italic>P. aeruginosa</italic> PAO1 utilising the Mascot&#x2122; V2.4.1 (Matrix Science) search engine. Mascot search parameters were set in accordance with published guidelines (<xref ref-type="bibr" rid="B96">Taylor and Goodlett, 2005</xref>) and to this end, fixed (carbamidomethyl &#x201c;C&#x201d;) and variable (oxidation &#x201c;M&#x201d; and deamidation &#x201c;N,Q&#x201d;) modifications were selected along with peptide (MS) and secondary fragmentation (MS/MS) tolerance values of 0.5Da whilst allowing for a single 13C isotope. Protein identifications obtained from each of the 21 individual gel slices per lane were compiled using the Meta-score protein compilation feature within the ProteinScape bioinformatics platform (<xref ref-type="bibr" rid="B11">Chamrad et al., 2003</xref>). From the compiled protein lists individual protein identifications were inspected manually and considered significant only if a) two peptides were matched for each protein, b) peptides were represented by a sequence coverage of &gt;5% and c) each matched peptide contained an unbroken &#x201c;b&#x201d; or &#x201c;y&#x201d; ion series represented by a minimum of four contiguous amino acid residues. The identification or absence of a protein in each treatment condition is only a semi-quantitative indication of relative abundance of proteins and individual leads need to be confirmed with further analysis.</p>
</sec>
</sec>
<sec id="s2_10">
<title>Preparation of Sterile <italic>P. aeruginosa</italic> Conditioned Media</title>
<p>
<italic>P. aeruginosa</italic> NH57388A (A) was cultured for 24 h at 37&#xb0;C in the presence of sub-inhibitory concentrations of cysteamine at 0, 2, 10, 20, 100 and 200 mg/L in cation-adjusted MHB (Thermo-Fisher, MA, USA). Culture supernatants were then clarified by centrifugation at 5,000 g for 5 min and then filter-sterilised by passing through a 0.22 &#xb5;M syringe-driven PES filter.</p>
</sec>
<sec id="s2_11">
<title>Assessment of the Toxicity of Secreted <italic>P. aeruginosa</italic> Factors Produced in Conditioned Media or Sputum in <italic>Galleria mellonella</italic>
</title>
<p>All <italic>Galleria mellonella</italic> larvae were purchased from Live Food UK Ltd (Rooks Bridge, UK) and, upon arrival, kept in wood shavings at 20&#xb0;C in the dark for 3 days prior to challenge. Larvae with approximate weight of 0.25&#x2013;0.30 g, which were not already melanized were assigned randomly to the different challenge groups or unmanipulated or vehicle control cohorts. Larvae were surface-sterilised with 70% ethanol. Ten microlitre volumes of vehicle control, or conditioned media was injected into the last left proleg as appropriate for each treatment using a 100 microlitre Hamilton syringe which was sterilized with ethanol and larvae were placed into separate sterile petri dishes at 37&#xb0;C. A melanisation score was determined by observation over time according to criteria described by <xref ref-type="bibr" rid="B46">Kay et&#xa0;al. (2019)</xref>, adapted from <xref ref-type="bibr" rid="B87">Senior et&#xa0;al. (2011)</xref>. Insects were considered dead when they become unresponsive to physical stimuli and turned black in colour. The toxicity of <italic>P. aeruginosa</italic> conditioned media was assessed with 10 larvae per treatment group. Survival was plotted using Kaplan-Meier survival distribution method and tested for statistical significance using Log-rank (Mantel-Cox) test.</p>
</sec>
<sec id="s2_12">
<title>Statistical Analysis</title>
<p>All statistical analysis was performed using GraphPad Prism 9.0.0. software using appropriate tests outlined in in the methods section above or in the figure legend.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Cysteamine Inhibited the Utilisation of Glycine in <italic>Pseudomonas aeruginosa</italic>
</title>
<p>Cysteamine has a high minimal inhibitory concentration (MIC) of 500 mg/L in glucose minimal media against <italic>P. aeruginosa</italic> strains (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>) and <xref ref-type="supplementary-material" rid="ST2">
<bold>Table S2</bold>
</xref>. Here we show that 200 mg/L has little effect on growth in either the &#x394;<italic>gcvP2</italic> mutant or PAO1 parent strain (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). However, cysteamine prevented the utilisation of glycine as a sole carbon source by <italic>P. aeruginosa</italic> PAO1 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>) as treatment with as little as 4 mg/L cysteamine completely prevented growth. As the <italic>gcs2</italic> cluster is responsible for glycine utilisation in <italic>P. aeruginosa</italic> and glycine decarboxylase is the target in mammalian cells we characterised the growth of &#x394;<italic>gcvP2</italic> mutant and PAO1 parent strain in glucose and glycine minimal media. As expected &#x394;<italic>gcvP2</italic> did not grow in glycine minimal media. The addition of high sub-inhibitory concentrations of cysteamine (200 mg/L) to growing cultures of the PAO1 parent and &#x394;<italic>gcvP2</italic> strains in M&#xfc;ller-Hinton broth caused glycine to accumulate in both the supernatant (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) and bacterial lysates (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>), but significant increases were only seen in the parent strain. Levels of glycine, in cysteamine-treated supernatants only, were above those of uninoculated M&#xfc;ller-Hinton broth, indicating that glycine is created during metabolism in this media but that it does not ordinarily accumulate. The &#x394;<italic>gcvP2</italic> strain had higher mean concentrations of glycine in the untreated pellets than the parent strain, though this was not significant (p=0.067).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>
<bold>(A)</bold> <italic>P. aeruginosa</italic> PAO1 and &#x394;<italic>gcvP2</italic> growth over time at 37&#xb0;C in M9 minimal media supplemented with 20 mM glucose with or without the addition of 200 mg/L cysteamine (n=3). <bold>(B)</bold> Only the PAO1 parent strain can grow in M9 supplemented with 20 mM glycine as the sole carbon source and 4 mg/L cysteamine prevents growth of the parent strain on this carbon source (n=3). <bold>(C)</bold> Glycine concentrations in bacterial culture supernatants grown for 24 h in cation-adjusted M&#xfc;ller-Hinton broth at 37&#xb0;C with or without the addition of 200 mg/L cysteamine (n=3). Glycine levels in media alone were unaffected by cysteamine and were calculated as 2871.42 &#xb1;121.63 ng/ml (standard deviation). **p &#x2264; 0.01, two-way ANOVA with Tukey&#x2019;s test. ns, not significant <bold>(D)</bold> Glycine concentrations in bacterial lysates from cultures grown for 24 h in cation-adjusted M&#xfc;ller-Hinton broth at 37&#xb0;C with or without the addition of 200 mg/L cysteamine (n=3). *p &#x2264; 0.05, Two-way ANOVA with Tukey&#x2019;s test. ns, not significant.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g001.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Electrospray Ionisation Tandem Mass Spectrometry Proteome Analysis of <italic>P. aeruginosa</italic> Exposed to Cysteamine</title>
<p>Whole cell proteomic analysis was conducted to examine the effect of cysteamine-mediated blockade on glycine utilisation by sub-inhibitory concentrations of cysteamine.</p>
<p>365 proteins were confidently identified by ESI tandem MS according to criteria outlined above. Fifteen proteins were found only in cysteamine-treated conditions across all replicates, and 66 proteins were confidently identified only in control conditions. The remaining 284 were confidently identified in both conditions. <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> lists proteins confidently identified only in cysteamine treated <italic>P. aeruginosa</italic> cells and <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> shows proteins only confidently identified in control conditions.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Proteins confidently identified only in the cysteamine-treated <italic>P. aeruginosa</italic> PAO1 cells according to criteria outlined by <xref ref-type="bibr" rid="B96">Taylor and Goodlett, 2005</xref>.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Treatment condition</th>
<th valign="top" align="center">Accession number</th>
<th valign="top" align="center">Protein name</th>
<th valign="top" align="center">Locus tag</th>
<th valign="top" align="center">Gene name</th>
<th valign="top" align="center">Function/pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Cysteamine treated</bold>
</td>
<td valign="top" align="center">NP_249916.1</td>
<td valign="top" align="left">FAD-dependent NADPH:quinone reductase</td>
<td valign="top" align="center">PA1225</td>
<td valign="top" align="center">mdaB</td>
<td valign="top" align="left">Oxidative stress</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251132.1</td>
<td valign="top" align="left">glycine cleavage system protein T2</td>
<td valign="top" align="center">PA2442</td>
<td valign="top" align="center">gcvT2</td>
<td valign="top" align="left">Glycine cleavage</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_252418.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA3729</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_253999.1</td>
<td valign="top" align="left">aldehyde dehydrogenase</td>
<td valign="top" align="center">PA5312</td>
<td valign="top" align="center">pauC</td>
<td valign="top" align="left">Polyamine catabolism</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251721.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA3031</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_253256.1</td>
<td valign="top" align="left">GTPase ObgE</td>
<td valign="top" align="center">PA4566</td>
<td valign="top" align="center">obgE</td>
<td valign="top" align="left">Response to stimulus</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_254244.1</td>
<td valign="top" align="left">ATP synthase F0F1 subunit delta</td>
<td valign="top" align="center">PA5557</td>
<td valign="top" align="center">atpH</td>
<td valign="top" align="left">ATP synthesis coupled proton transport</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_249578.1</td>
<td valign="top" align="left">acetyl-CoA synthetase</td>
<td valign="top" align="center">PA0887</td>
<td valign="top" align="center">acsA</td>
<td valign="top" align="left">Acetate utilisation</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_254101.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA5414</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251872.1</td>
<td valign="top" align="left">6-phosphogluconolactonase</td>
<td valign="top" align="center">PA3182</td>
<td valign="top" align="center">pgl</td>
<td valign="top" align="left">Pentose phosphate pathway</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_250981.1</td>
<td valign="top" align="left">glucose-sensitive porin</td>
<td valign="top" align="center">PA2291</td>
<td valign="top" align="center">oprB2/opbA</td>
<td valign="top" align="left">Glucose uptake</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_253007.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA4317</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_249540.1</td>
<td valign="top" align="left">thioredoxin reductase</td>
<td valign="top" align="center">PA0849</td>
<td valign="top" align="center">trxB2</td>
<td valign="top" align="left">Removal of superoxide radicals</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251134.1</td>
<td valign="top" align="left">serine hydroxymethyltransferase</td>
<td valign="top" align="center">PA2444</td>
<td valign="top" align="center">glyA2</td>
<td valign="top" align="left">Glycine biosynthesis, tetrahydrofolate interconversion</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251992.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA3302</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="center">NP_251148.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA2458</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Proteins confidently identified only in the control <italic>P. aeruginosa</italic> PAO1 cells according to criteria outlined by <xref ref-type="bibr" rid="B96">Taylor and Goodlett, 2005</xref>.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Treatment condition</th>
<th valign="top" align="center">Accession number</th>
<th valign="top" align="center">Protein name</th>
<th valign="top" align="center">Locus tag</th>
<th valign="top" align="center">Gene name</th>
<th valign="top" align="center">Function/pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" rowspan="67" align="left">
<bold>Control</bold>
</td>
<td valign="top" align="center">NP_252997.1</td>
<td valign="top" align="left">chemotactic transducer</td>
<td valign="top" align="center">PA4307</td>
<td valign="top" align="center">pctC</td>
<td valign="top" align="left">Chemotaxis, response to amino acid, signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_252999.1</td>
<td valign="top" align="left">chemotactic transducer</td>
<td valign="top" align="center">PA4309</td>
<td valign="top" align="center">pctA</td>
<td valign="top" align="left">Chemotaxis, response to amino acid, signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_254241.1</td>
<td valign="top" align="left">ATP synthase F0F1 subunit beta</td>
<td valign="top" align="center">PA5554</td>
<td valign="top" align="center">atpD</td>
<td valign="top" align="left">Produces ATP from ADP in the presence of a proton gradient across the membrane. The catalytic sites are hosted primarily by the beta subunits.</td>
</tr>
<tr>
<td valign="top" align="center">NP_253259.1</td>
<td valign="top" align="left">octaprenyl-diphosphate synthase</td>
<td valign="top" align="center">PA4569</td>
<td valign="top" align="center">ispB</td>
<td valign="top" align="left">Isoprenoid synthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_064729.1</td>
<td valign="top" align="left">glycyl-tRNA synthetase subunit alpha</td>
<td valign="top" align="center">PA0009</td>
<td valign="top" align="center">glyQ</td>
<td valign="top" align="left">Translation. Transfer of glycine amino acid to nascent peptides</td>
</tr>
<tr>
<td valign="top" align="center">NP_250378.1</td>
<td valign="top" align="left">spermidine synthase</td>
<td valign="top" align="center">PA1687</td>
<td valign="top" align="center">speE</td>
<td valign="top" align="left">Polyamine synthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_250243.1</td>
<td valign="top" align="left">cytochrome C oxidase cbb3-type subunit</td>
<td valign="top" align="center">PA1552</td>
<td valign="top" align="center">ccoP1</td>
<td valign="top" align="left">Electron transport chain</td>
</tr>
<tr>
<td valign="top" align="center">NP_248735.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA0045</td>
<td valign="top" align="center">csgG</td>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_252294.1</td>
<td valign="top" align="left">response regulator</td>
<td valign="top" align="center">PA3604</td>
<td valign="top" align="center">erdR</td>
<td valign="top" align="left">Ethanol detoxification</td>
</tr>
<tr>
<td valign="top" align="center">NP_251020.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA2330</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_252750.1</td>
<td valign="top" align="left">thioredoxin</td>
<td valign="top" align="center">PA4061</td>
<td valign="top" align="center">YbbN</td>
<td valign="top" align="left">Glycerol ether metabolic process, cell redox homeostasis</td>
</tr>
<tr>
<td valign="top" align="center">NP_251251.1</td>
<td valign="top" align="left">chemotaxis transducer</td>
<td valign="top" align="center">PA2561</td>
<td valign="top" align="center">ctpH</td>
<td valign="top" align="left">Chemotaxis, detection of phosphate ion, signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_249783.1</td>
<td valign="top" align="left">flagellin type B</td>
<td valign="top" align="center">PA1092</td>
<td valign="top" align="center">fliC</td>
<td valign="top" align="left">Swimming motility</td>
</tr>
<tr>
<td valign="top" align="center">NP_249688.1</td>
<td valign="top" align="left">PqsB protein</td>
<td valign="top" align="center">PA0997</td>
<td valign="top" align="center">pqsB</td>
<td valign="top" align="left">Quorum sensing</td>
</tr>
<tr>
<td valign="top" align="center">NP_253277.1</td>
<td valign="top" align="left">cytochrome C551 peroxidase</td>
<td valign="top" align="center">PA4587</td>
<td valign="top" align="center">ccpR</td>
<td valign="top" align="left">Oxidation-reduction processes</td>
</tr>
<tr>
<td valign="top" align="center">NP_254114.1</td>
<td valign="top" align="left">alcohol dehydrogenase</td>
<td valign="top" align="center">PA5427</td>
<td valign="top" align="center">adhA</td>
<td valign="top" align="left">Ethanol detoxification</td>
</tr>
<tr>
<td valign="top" align="center">NP_253754.1</td>
<td valign="top" align="left">phosphoribosyl-ATP pyrophosphatase</td>
<td valign="top" align="center">PA5067</td>
<td valign="top" align="center">hisE</td>
<td valign="top" align="left">Histidine biosynthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_251985.1</td>
<td valign="top" align="left">HIT family protein</td>
<td valign="top" align="center">PA3295</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_253563.1</td>
<td valign="top" align="left">OsmE family transcriptional regulator</td>
<td valign="top" align="center">PA4876</td>
<td valign="top" align="center">osmE</td>
<td valign="top" align="left">Response to stimulus</td>
</tr>
<tr>
<td valign="top" align="center">NP_249102.1</td>
<td valign="top" align="left">twitching motility protein</td>
<td valign="top" align="center">PA0411</td>
<td valign="top" align="center">pilJ</td>
<td valign="top" align="left">Signal transduction, chemotaxis, pilin biosynthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_252082.1</td>
<td valign="top" align="left">nitrous-oxide reductase</td>
<td valign="top" align="center">PA3392</td>
<td valign="top" align="center">nosZ</td>
<td valign="top" align="left">Denitrification pathway</td>
</tr>
<tr>
<td valign="top" align="center">NP_250368.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA1677</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_248992.1</td>
<td valign="top" align="left">polyamine transporter</td>
<td valign="top" align="center">PA0301</td>
<td valign="top" align="center">spuE</td>
<td valign="top" align="left">Polyamine transport</td>
</tr>
<tr>
<td valign="top" align="center">NP_253335.1</td>
<td valign="top" align="left">uracil phosphoribosyltransferase</td>
<td valign="top" align="center">PA4646</td>
<td valign="top" align="center">upp</td>
<td valign="top" align="left">UMP biosynthesis <italic>via</italic> salvage pathway</td>
</tr>
<tr>
<td valign="top" align="center">NP_253991.1</td>
<td valign="top" align="left">D-amino acid dehydrogenase small subunit</td>
<td valign="top" align="center">PA5304</td>
<td valign="top" align="center">dadA</td>
<td valign="top" align="left">D-amino acid metabolic process, phenylalinine metabolic process</td>
</tr>
<tr>
<td valign="top" align="center">NP_252548.1</td>
<td valign="top" align="left">carboxylesterase</td>
<td valign="top" align="center">PA3859</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Carboxylic ester hydrolase activity</td>
</tr>
<tr>
<td valign="top" align="center">NP_248816.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA0126</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_252508.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA3819</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Rick_17kDa_Anti domain-containing protein</td>
</tr>
<tr>
<td valign="top" align="center">NP_251263.1</td>
<td valign="top" align="left">chemotaxis transducer</td>
<td valign="top" align="center">PA2573</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_252331.1</td>
<td valign="top" align="left">amino acid permease</td>
<td valign="top" align="center">PA3641</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Sodium/alanine symporter</td>
</tr>
<tr>
<td valign="top" align="center">NP_253795.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA5108</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_249700.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA1009</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_249342.1</td>
<td valign="top" align="left">indole-3-glycerol phosphate synthase</td>
<td valign="top" align="center">PA0651</td>
<td valign="top" align="center">trpC</td>
<td valign="top" align="left">Tryptophan biosynthesis/metabolism</td>
</tr>
<tr>
<td valign="top" align="center">NP_253323.1</td>
<td valign="top" align="left">chemotaxis transducer</td>
<td valign="top" align="center">PA4633</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_253619.1</td>
<td valign="top" align="left">50S ribosomal protein L9</td>
<td valign="top" align="center">PA4932</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Translation</td>
</tr>
<tr>
<td valign="top" align="center">NP_253821.1</td>
<td valign="top" align="left">carboxyl-terminal protease</td>
<td valign="top" align="center">PA5134</td>
<td valign="top" align="center">ctpA</td>
<td valign="top" align="left">Cell envelope organisation, cell wall biogenesis, pathogenesis, protein secretion by the type III secretion system, signal transduction</td>
</tr>
<tr>
<td valign="top" align="center">NP_252016.1</td>
<td valign="top" align="left">ATP-dependent Clp protease proteolytic subunit</td>
<td valign="top" align="center">PA3326</td>
<td valign="top" align="center">clpP2</td>
<td valign="top" align="left">Proteolysis</td>
</tr>
<tr>
<td valign="top" align="center">NP_251816.1</td>
<td valign="top" align="left">heat-shock protein IbpA</td>
<td valign="top" align="center">PA3126</td>
<td valign="top" align="center">ibpA</td>
<td valign="top" align="left">Protein folding</td>
</tr>
<tr>
<td valign="top" align="center">NP_250219.1</td>
<td valign="top" align="left">cell division protein</td>
<td valign="top" align="center">PA1528</td>
<td valign="top" align="center">zipA</td>
<td valign="top" align="left">Division septum assembly, FtsZ-dependent cytokinesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_253376.1</td>
<td valign="top" align="left">ferric iron-binding periplasmic protein</td>
<td valign="top" align="center">PA4687</td>
<td valign="top" align="center">hitA</td>
<td valign="top" align="left">Iron ion homeostasis</td>
</tr>
<tr>
<td valign="top" align="center">NP_252347.1</td>
<td valign="top" align="left">methionine aminopeptidase</td>
<td valign="top" align="center">PA3657</td>
<td valign="top" align="center">map</td>
<td valign="top" align="left">Cellular protein metabolic process</td>
</tr>
<tr>
<td valign="top" align="center">NP_253430.1</td>
<td valign="top" align="left">tRNA pseudouridine synthase B</td>
<td valign="top" align="center">PA4742</td>
<td valign="top" align="center">truB</td>
<td valign="top" align="left">RNA metabolic processes</td>
</tr>
<tr>
<td valign="top" align="center">NP_251543.1</td>
<td valign="top" align="left">outer membrane lipoprotein</td>
<td valign="top" align="center">PA2853</td>
<td valign="top" align="center">oprI</td>
<td valign="top" align="left">Outer membrane protein</td>
</tr>
<tr>
<td valign="top" align="center">NP_253085.1</td>
<td valign="top" align="left">nucleotide-binding protein</td>
<td valign="top" align="center">PA4395</td>
<td valign="top" align="center">yajQ</td>
<td valign="top" align="left">Unknown</td>
</tr>
<tr>
<td valign="top" align="center">NP_253132.1</td>
<td valign="top" align="left">bifunctional sulfate adenylyltransferase subunit 1/adenylylsulfate kinase</td>
<td valign="top" align="center">PA4442</td>
<td valign="top" align="center">cysNC</td>
<td valign="top" align="left">hydrogen sulfide biosynthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_250493.1</td>
<td valign="top" align="left">ATP-dependent protease ATP-binding subunit ClpX</td>
<td valign="top" align="center">PA1802</td>
<td valign="top" align="center">clpX</td>
<td valign="top" align="left">Protein folding</td>
</tr>
<tr>
<td valign="top" align="center">NP_251342.1</td>
<td valign="top" align="left">chemotaxis transducer</td>
<td valign="top" align="center">PA2652</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Cellular response to an organic substance, chemotaxis</td>
</tr>
<tr>
<td valign="top" align="center">NP_250759.1</td>
<td valign="top" align="left">carbamoyl transferase</td>
<td valign="top" align="center">PA2069</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Biosynthetic processes, nodulation</td>
</tr>
<tr>
<td valign="top" align="center">NP_250734.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA2044</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_249345.1</td>
<td valign="top" align="left">S-adenosylmethionine decarboxylase</td>
<td valign="top" align="center">PA0654</td>
<td valign="top" align="center">speD</td>
<td valign="top" align="left">Spermidine biosynthetic process</td>
</tr>
<tr>
<td valign="top" align="center">NP_250439.1</td>
<td valign="top" align="left">enoyl-CoA hydratase</td>
<td valign="top" align="center">PA1748</td>
<td valign="top" align="center"/>
<td valign="top" align="left"/>
</tr>
<tr>
<td valign="top" align="center">NP_249090.1</td>
<td valign="top" align="left">cystathionine beta-synthase</td>
<td valign="top" align="center">PA0399</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Cysteine biosynthetic process from serine</td>
</tr>
<tr>
<td valign="top" align="center">NP_248924.1</td>
<td valign="top" align="left">transcriptional regulator</td>
<td valign="top" align="center">PA0233</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Regulation of transcription</td>
</tr>
<tr>
<td valign="top" align="center">NP_249020.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA0329</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_253705.1</td>
<td valign="top" align="left">peptide methionine sulfoxide reductase</td>
<td valign="top" align="center">PA5018</td>
<td valign="top" align="center">msrA/pmsR</td>
<td valign="top" align="left">Cellular response to oxidative stress</td>
</tr>
<tr>
<td valign="top" align="center">NP_253559.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA4872</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_250270.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA1579</td>
<td valign="top" align="center"/>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_251947.1</td>
<td valign="top" align="left">periplasmic tail-specific protease</td>
<td valign="top" align="center">PA3257</td>
<td valign="top" align="center">algO/prc</td>
<td valign="top" align="left">Signal transduction, proteolysis</td>
</tr>
<tr>
<td valign="top" align="center">NP_253977.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA5290</td>
<td valign="top" align="center">yifB</td>
<td valign="top" align="left">Uncharacterised</td>
</tr>
<tr>
<td valign="top" align="center">NP_253012.1</td>
<td valign="top" align="left">hypothetical protein</td>
<td valign="top" align="center">PA4322</td>
<td valign="top" align="center"/>
<td valign="top" align="left">AAA domain-containing protein, ATPase activity, ATP binding</td>
</tr>
<tr>
<td valign="top" align="center">NP_251853.1</td>
<td valign="top" align="left">cytidylate kinase</td>
<td valign="top" align="center">PA3163</td>
<td valign="top" align="center">cmk</td>
<td valign="top" align="left">Nucleobase-containing small molecule interconversion, pyrimidine nucleotide metabolic process</td>
</tr>
<tr>
<td valign="top" align="center">NP_254112.1</td>
<td valign="top" align="left">phosphoribosylaminoimidazole carboxylase ATPase subunit</td>
<td valign="top" align="center">PA5425</td>
<td valign="top" align="center">purK</td>
<td valign="top" align="left">IMP biosynthesis <italic>via de novo</italic> pathway</td>
</tr>
<tr>
<td valign="top" align="center">NP_249563.1</td>
<td valign="top" align="left">phenylalanine 4-monooxygenase</td>
<td valign="top" align="center">PA0872</td>
<td valign="top" align="center">phhA</td>
<td valign="top" align="left">Tyrosine biosynthesis, L-phenylalanine catabolism</td>
</tr>
<tr>
<td valign="top" align="center">NP_253137.1</td>
<td valign="top" align="left">histidinol-phosphate aminotransferase</td>
<td valign="top" align="center">PA4447</td>
<td valign="top" align="center">hisC1</td>
<td valign="top" align="left">L-histidine biosynthesis</td>
</tr>
<tr>
<td valign="top" align="center">NP_252221.1</td>
<td valign="top" align="left">bacterioferritin</td>
<td valign="top" align="center">PA3531</td>
<td valign="top" align="center">bfrB</td>
<td valign="top" align="left">Intracellular sequestering of iron</td>
</tr>
<tr>
<td valign="top" align="center">NP_250946.1</td>
<td valign="top" align="left">paerucumarin biosynthesis protein PvcC</td>
<td valign="top" align="center">PA2256</td>
<td valign="top" align="center">pvcC</td>
<td valign="top" align="left">Iron chelation</td>
</tr>
<tr>
<td valign="top" align="center">NP_249644.1</td>
<td valign="top" align="left">thioredoxin</td>
<td valign="top" align="center">PA0953</td>
<td valign="top" align="center">helX (DsbE)</td>
<td valign="top" align="left">Antioxidant activity, oxidoreductase activity</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Although the glycine dehydrogenase (decarboxylating) proteins encoded by <italic>gcvP1</italic> and <italic>gcvP2</italic> were not amongst the proteins detected with confidence in either cysteamine treated or controls, the neighbouring serine hydroxymethyltransferase (GlyA2) and glycine cleavage system protein T2 (GcvT2) were only confidently detected in cysteamine treated cells, suggesting an increased protein abundance in this condition. The glycyl tRNA synthetase (<italic>glyQ</italic>) was amongst the proteins found only in the control condition.</p>
<p>Also of interest, the FAD-dependent NADPH:quinone reductase, MdaB (modulator of drug activity B), was identified only in the cysteamine treated condition. This has been implicated in the detoxification of certain compounds and it is linked to quinone and REDOX cycling (<xref ref-type="bibr" rid="B1">Adams et&#xa0;al., 2005</xref>). It is not known if this is involved in a shift in NADP : NADPH ratio previously reported to be induced by cysteamine (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>).</p>
<p>Chemotaxis proteins PctA, PctC, CtpH, PA4633 and PA2652 were amongst those identified only in control conditions. Flagellin (the structural unit of the bacterial flagellum) and the twitching motility protein PilJ, were also only detected in the&#xa0;control condition. This provided the rationale to investigate the potential for cysteamine to inhibit chemotaxis and chemotactic swimming and swarming motility (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>
<italic>C. elegans</italic> paralysis assay, HCN production, and chemotaxis and motility assays. <bold>(A)</bold> Both the PAO1 parent strain and the &#x394;<italic>gcvP2</italic> mutant induced paralysis in <italic>C. elegans</italic> over time. The &#x394;<italic>gcvP2</italic> mutant produced significantly higher levels of paralysis than the parent strain. Cysteamine provided dose-dependent protection from paralysis in both mutant and parent strain, suggesting cysteamine inhibited the HCN produced by <italic>P. aeruginosa</italic> cultures. *p &#x2264; 0.05, **p &#x2264; 0.01, ***p &#x2264; 0.001, ****p &#x2264; 0.0001 two-way ANOVA and &#x160;id&#xe1;k&#x2019;s multiple comparisons test. <bold>(B)</bold> Colorimetric detection of volatile HCN produced by <italic>P. aeruginosa</italic> PAO1 and &#x394;gcvP2 mutant grown for the same time (n=3) showed that the mutant liberated more HCN. Experiments on 2-compartment agar plates with either MHA alone (-) or supplemented (+) with sub-inhibitory 200 mg/L cysteamine showed that HCN production in both the mutant and the parent strain were inhibited by cysteamine. <bold>(C)</bold> Chemotactic swimming motility of both PAO1 and the &#x394;gcvP2 mutant on 0.3% M9 agar containing 20 mM glucose was inhibited by the addition of 200 mg/L cysteamine at 48 h, as demonstrated by the abolition of concentric rings. Swarming motility, as defined by dendritic outgrowth, was also inhibited on 0.3% agar containing 0.2% w/v casamino acids at 24 h and 48 h, and the effect on pigment production is also evident (Representative images from n=3).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g002.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Cysteamine Inhibits HCN Production</title>
<p>Glycine is converted into HCN by <italic>P. aeruginosa</italic> by the contiguous HCN synthase genes <italic>hcnABC.</italic> A blockade of glycine cleavage by cysteamine in <italic>P. aeruginosa</italic> might be expected to raise glycine levels, as it does when administered to rats (<xref ref-type="bibr" rid="B43">Iwama et&#xa0;al., 1997</xref>). Mutation in the <italic>gcsR</italic> gene, a TyrR-like enhancer-binding protein of the alternative sigma factor RpoN (&#x3c3;<sup>54</sup>) which regulates the glycine cleavage system in <italic>P. aeruginosa</italic> PAO1 (<xref ref-type="bibr" rid="B85">Sarwar et al., 2016</xref>), was demonstrated to enhance HCN-dependent paralytic-killing in the <italic>Caenorhabditis elegans</italic> model. HCN production is also known to be under the control of the hierarchical quorum sensing system in <italic>P. aeruginosa</italic>.</p>
<p>We examined the effects of cysteamine on the production of HCN by the &#x394;<italic>gcvP2</italic> mutant and the parent PAO1 We did this by comparing the ability of PAO1 and &#x394;<italic>gcvP2</italic> to induce paralysis in a <italic>C. elegans</italic> model (<xref ref-type="bibr" rid="B16">Darby et&#xa0;al., 1999</xref>), and examined any effect of the incorporation of cysteamine into the growth media on the ability of each strain to induce paralysis (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). We also examined HCN production directly by incorporating sub-inhibitory concentrations of cysteamine into agar plates seeded with lawns of each isolate and detecting volatile HCN produced during culture over time (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>).</p>
<p>Despite effective blockade of glycine utilisation by cysteamine in <italic>P. aeruginosa</italic> at 4 mg/L (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>), the incorporation of cysteamine (at 200 mg/L) into MHA plates surprisingly inhibits the production of HCN, despite having no effect on bacterial growth. The &#x394;<italic>gcvP2</italic> mutant produced more HCN than the PAO1 parent strain over the same incubation time, and induced paralysis in <italic>C. elegans</italic> quicker than the parent strain, probably due to increased substrate availability. Cysteamine also dose-dependently protected <italic>C. elegans</italic> from paralysis (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A, B</bold>
</xref>).</p>
<p>Cysteamine also had a marked effect on chemotaxis on semi-solid (0.3% agar) media containing glucose as the sole carbon source. Radial growth was apparent in control conditions at 48 h for both the parent strain and &#x394;<italic>gcvP2</italic> and both were impacted by the incorporation of cysteamine into the growth media, as surface growth out from the central inoculum was reduced and disorganised. When grown on 0.2% w/v casamino acids medium there is evidence of swarming motility, indicated by dendritic outgrowth from the inoculum, in both mutant and parent strain which is inhibited by cysteamine. The impact on pigment production was also particularly evident when grown on casamino acids (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). The inclusion of cysteamine also impacted on the area of growth, with significant reductions in growth area for both the parent strain and &#x394;<italic>gcvP2</italic> mutant on agar containing 0.2% w/v casamino acids at 24 and 48 h. Cysteamine reductions in growth on 20 mM glucose were less evident at 24 h and only significant for the &#x394;<italic>gcvP2</italic> mutant at 48 h (<xref ref-type="supplementary-material" rid="SF1">
<bold>Figure S1</bold>
</xref>).</p>
</sec>
<sec id="s3_4">
<title>Inhibition of Exopolysaccharide Production</title>
<p>Exopolysaccharide (EPS) production is important for biofilm formation which is critical for <italic>P. aeruginosa</italic> chronic infection of the CF lung (H&#xf8;iby, Ciofu and Bjarnsholt, 2010), at least three exopolysaccharides contribute toward biofilm production, including Psl, Pel and alginate (Reviewed by <xref ref-type="bibr" rid="B30">Ghafoor et&#xa0;al., 2011</xref>). Cysteamine significantly inhibited the amount of EPS secreted by mucoid <italic>P. aeruginosa</italic> strain NH57388A into (and precipitated from) culture media and, as expected, the non-mucoid quorum sensing mutant NH57388B produced significantly less exopolysaccharide than NH57388A (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). Cysteamine had a significant effect on the exopolysaccharide secreted by both the alginate-producing NH57388A strain and the non-mucoid NH57388B at high sub-inhibitory concentrations.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Cysteamine inhibits exopolysaccharide, pyoverdine and pyocyanin production. <bold>(A)</bold> Exopolysaccharide precipitated from sterile-filtered MHB culture supernatants of <italic>P. aeruginosa</italic> strains NH57388A and NH57388B with acidified Alcian blue following culture for 48 h at 37&#xb0;C. Quantification of exopolysaccharide secreted into culture supernatant by NH57388A mucoid strain treated with cysteamine at 2 and 200 mg/L for 48 h at 37&#xb0;C. ****p &#x2264; 0.0001 one-way ANOVA and Dunnet&#x2019;s multiple comparison test, ns, not significant (n=3). Cysteamine had a dose-dependent inhibitory effect on exopolysaccharide secreted from mucoid NH57388A and non-mucoid quorum sensing deficient NH57388B strains. <bold>(B)</bold> Cysteamine-mediated inhibition of pyocyanin production by <italic>P. aeruginosa</italic> strains PAO1, PA14 and NH57388A following 20 h treatment at 37&#xb0;C with the concentration range shown. *p &#x2264; 0.05, **p &#x2264; 0.01, ****p = &lt; 0.0001, One-way ANOVA and Tukey&#x2019;s test (n=3). <bold>(C)</bold> Inhibition of pyoverdine expression after 20 h growth in MHB by cysteamine at 200 mg/L in multiple strains as detected by fluorescence at 400/460 ex/em normalised to absorbance at 625 nm and compared with quenching induced by excess iron (1 mM Fe(III)Cl3). ****p = &lt; 0.0001, Two-way ANOVA and Tukey&#x2019;s test (n=3).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g003.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Cysteamine Inhibits the Production of Pyocyanin and Pyoverdine</title>
<p>Here we quantify the effect of a range of cysteamine doses on pyocyanin (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>) secreted by <italic>P. aeruginosa</italic> PAO1 type strain, NH57388A alginate-producing strain and PA14 clinical strains grown in MHB. We also demonstrate that sub-inhibitory concentrations of cysteamine inhibit pyoverdine fluorescence (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>).</p>
</sec>
<sec id="s3_6">
<title>Cysteamine Reduces Tobramycin-Mediated Biofilm Induction</title>
<p>Aminoglycosides are routinely used for the control of <italic>P. aeruginosa</italic> in CF patients, including short-term parenteral administration during pulmonary exacerbations and chronic use as inhalation therapies. The tobramycin inhalation powder is safe, efficacious (<xref ref-type="bibr" rid="B29">Geller et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B49">Konstan et&#xa0;al., 2011</xref>) and has been adopted for routine chronic use for patients colonised with <italic>P. aeruginosa</italic> for some time, mainly owing to superior convenience, and therefore improved patient compliance, over nebulised therapies (<xref ref-type="bibr" rid="B5">Blasi et&#xa0;al., 2018</xref>). Tobramycin inhalation is known to improve lung function over time, and reduce the exacerbation rate (<xref ref-type="bibr" rid="B93">Smith et&#xa0;al., 2018</xref>). At the same time exposure to sub-inhibitory concentrations of tobramycin is known to induce biofilm formation by <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B39">Hoffman et&#xa0;al., 2005</xref>) including in CF isolates, independent of minimum inhibitory concentration (MIC) and resistance status (<xref ref-type="bibr" rid="B22">Elliott et&#xa0;al., 2010</xref>). RpoN is known to play a role in tobramycin tolerance and biofilm formation (<xref ref-type="bibr" rid="B57">Lloyd et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B100">Viducic et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B88">Shao et&#xa0;al., 2018</xref>).</p>
<p>Here we examined the effect of combining sub-inhibitory concentrations of cysteamine and tobramycin together on the&#xa0;attachment of <italic>P. aeruginosa</italic> clinical strain PA14 to polystyrene plates using the modified crystal violet method (<xref ref-type="bibr" rid="B73">O&#x2019;Toole, et&#xa0;al, 1999</xref>). Although sub-inhibitory concentrations of some other antibiotics can induce biofilm formation, tobramycin was chosen due to its use as an inhalation maintenance therapy in CF, and PA14 was selected due to clinical relevance. Tobramycin impaired planktonic growth at 0.2 mg/L but encouraged biofilm formation, whereas cysteamine at 2 mg/L had no impact on planktonic growth at all, alone or in combination with tobramycin at this concentration. However, the combination of tobramycin and cysteamine significantly reduced the biofilm formation (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). The disulfide, cystamine, had no effect on biofilm formation at 24 h.</p>
</sec>
<sec id="s3_7">
<title>Cysteamine Inhibited <italic>P. aeruginosa</italic> Virulence in <italic>G. mellonella</italic> Model</title>
<p>We have already demonstrated potentiation of ciprofloxacin and tobramycin against <italic>P. aeruginosa</italic> in different murine infection models (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>), but the degree to which inhibition of bacterial virulence factor production contributed to enhanced antimicrobial efficacy is difficult to assess and was not examined at the time. The larvae of the wax moth <italic>G. mellonella</italic> have been developed as a non-mammalian <italic>in vivo</italic> infection model which has now been used extensively to test antimicrobial agents. <italic>P. aeruginosa</italic> has strain-dependent virulence in this model, which correlates well to virulence in mice (<xref ref-type="bibr" rid="B44">Jander et&#xa0;al., 2000</xref>). Although some <italic>P. aeruginosa</italic> virulence mechanisms are contact-dependent, many are secreted, so we have assessed the toxicity of sterile-filtered culture supernatants derived from <italic>P. aeruginosa</italic> strains at equal cell densities, treated with different sub-inhibitory concentrations of cysteamine for 20 h at 37&#xb0;C prior to injection into the insect haemolymph. The lethality of <italic>Pseudomonas</italic> infection in <italic>G. mellonella</italic> can be extreme and varies widely between strains (<xref ref-type="bibr" rid="B14">Cullen et&#xa0;al., 2015</xref>). Therefore, we decided to examine sterile-filtered supernatants from cultures of <italic>P. aeruginosa</italic>, using the less virulent mucoid strain, NH57388A</p>
<p>Exposure to 2, 20, 100 and 200 mg/L cysteamine significantly reduced the toxicity of sterile-filtered supernatants of NH57388A in <italic>G. mellonella</italic> (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>) and reduced the rapid melanisation seen at 1 h post injection.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>
<bold>(A)</bold> Cysteamine inhibited the toxicity of microbial secreted factors toward<italic> G. mellonella</italic> produced in culture. <italic>P. aeruginosa</italic> NH57388A was cultured for 24 h at 37&#xb0;C in the presence of cysteamine at 0, 2, 10, 20, 100 and 200 mg/L and 10 &#xb5;l volumes of sterile-filtered supernatants were injected into <italic>G. mellonella</italic> larvae and survival recorded over 48 h. *p &#x2264; 0.05, **p &#x2264; 0.01 log-rank (Mantel-Cox) test, ns, not significant. <bold>(B)</bold> Melanisation in response to <italic>P. aeruginosa</italic> secreted factors was rapid as illustrated by the change in melanisation score over time and inhibited by cysteamine. Scoring criteria developed by <xref ref-type="bibr" rid="B46">Kay et al. (2019)</xref> are as follows: 1. No signs of melanisation, 2. Signs of nodulation and lateral line melanisation, 3. Systemic melanisation (&gt;50%), 4. Deceased (no movement for 20 min) with full systemic melanisation).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Cysteamine was found to inhibit multiple aspects of <italic>P. aeruginosa</italic> virulence building upon previous data demonstrating antibiofilm activity and the ability to reduce pigment production. Results presented here demonstrate for the first time that cysteamine can inhibit glycine utilisation in prokaryotic cells, but the links between this metabolic disruption and virulence factor production are not known. We also demonstrate inhibition of HCN and exopolysaccharide production and that cysteamine (at therapeutically achievable doses) hinders biofilm formation induced by tobramycin.</p>
<sec id="s4_1">
<title>Inhibition of Glycine Utilisation and Links to Virulence</title>
<p>Cysteamine inhibits the evolutionary well-conserved glycine cleavage system in mammalian cells. This system is found on the inner membrane of mitochondria in mammalian cells and is composed of H, P, L and T proteins. It has been reported that cysteamine increases the Km for glycine and V<sub>max</sub> for the P-protein (<xref ref-type="bibr" rid="B35">Hayasaka and Tada, 1983</xref>), and is reported to prevent both glycine oxidation and synthesis (<xref ref-type="bibr" rid="B111">Yudkoff et&#xa0;al., 1981</xref>). <italic>P. aeruginosa</italic> PAO1 encodes two copies of <italic>gcvH</italic>, <italic>gcvP</italic> and <italic>gcvT</italic> genes and has three copies of the serine hydroxymethyltransferase gene <italic>glyA</italic> which converts glycine to serine and plays an important role in the generation of one carbon units for methylation as well as (together with serine dehydratase) conversion to pyruvate for utilisation as a sole carbon (or nitrogen) source (<xref ref-type="bibr" rid="B85">Sarwar et&#xa0;al., 2016</xref>). The inability to utilise glycine in the presence of small concentrations of cysteamine (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) could be indicative of a similar blockade.</p>
<p>Inhibition of glycine cleavage could be expected to interfere with bacterial C1 metabolism and methylation. The relative abundance of methyl-accepting chemotaxis proteins (MCPs) may be reduced by cysteamine, with the proteins CtpH, PctA, and PctB are amongst those identified by proteomics only in control conditions (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). The same chemotaxis proteins have been implicated in virulence by Sheng et al., 2019, which demonstrate inhibition of these MCPs (plus CtpM and others) by overexpression of MapZ, a c-di-GMP-dependent inhibitor of methylation of MCPs protected mice in an intraperitoneal model of acute infection. Generation of the second messenger c-di-GMP is directly linked to the glycine cleavage system <italic>via</italic> serine hydroxymethyltransferase (ShrA/GlyA2) in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B80">Pu et&#xa0;al., 2018</xref>) and high levels of c-di-GMP are linked to chronic virulence traits including exopolysaccharide production (<xref ref-type="bibr" rid="B56">Lee et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B13">Chung et&#xa0;al., 2008</xref>), alginate polymerisation and export <italic>via</italic> Alg44 (<xref ref-type="bibr" rid="B2">Amikam and Galperin, 2006</xref>; <xref ref-type="bibr" rid="B62">Merighi et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B71">Oglesby et&#xa0;al., 2008</xref>), biofilm formation (<xref ref-type="bibr" rid="B38">Hickman et&#xa0;al., 2005</xref>), and antibiotic efflux (<xref ref-type="bibr" rid="B69">Nicastro et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B79">Poudyal and Sauer, 2018</xref>; <xref ref-type="bibr" rid="B101">Wang et&#xa0;al., 2018</xref>).</p>
<p>In the proteomics data GcvT2 and GlyA2 were only identified in the cysteamine-treated condition (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). In combination with a lack of detectable glycyl tRNA synthetase (GlyQ) in cysteamine treated conditions, it is tempting to speculate that these alterations are a direct feedback response to the inhibition of glycine decarboxylation, and the corresponding increase in glycine abundance (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>). Whilst we confirmed cysteamine has impacts on swimming and swarming chemotactic behaviours (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>) there was an equal effect on both the &#x394;<italic>gcvP2</italic> and parent strain. <italic>P. aeruginosa</italic> possesses two glycine cleavage operons therefore it could be that any impact on chemotaxis in the &#x394;<italic>gcvP2</italic> mutant is compensated by secondary activity of <italic>gcvP1</italic>, or that cysteamine disrupts chemotaxis <italic>via</italic> a different mechanism. The measurement of glycine in bacterial lysates and supernatants confirmed cysteamine-mediated disruption of glycine utilisation as glycine was increased in cysteamine treated PAO1 cells (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1C, D</bold>
</xref>). Although the increase was only significant in the parent strain, mean increases in glycine were seen in the mutant also, which may suggest the <italic>gcvP1</italic> has residual activity impaired by cysteamine treatment and this is worthy of future investigation.</p>
<p>The glycine cleavage system was initially linked to the production of pyocyanin <italic>via</italic> the TyrR-like enhancer-binding protein (EBP) GcsR (PA2449) believed to regulate the <italic>gsc2</italic> operon, which includes <italic>gcvH2, gcvP2, glyA2, sdaA</italic>, and <italic>gcvT2</italic> encoding some of the proteins mentioned above found in cysteamine-treated cells (<xref ref-type="bibr" rid="B59">Lundgren et&#xa0;al., 2013</xref>). However, this was subsequently disproved by the same group who determined the inhibition of pyocyanin in the initial study was due to unrelated mutations. This study confirmed the EBP nature of GcsR which enhances the transcriptional activity of RpoN upstream of the <italic>gsc2</italic> operon. As discussed above, the &#x394;<italic>gscR</italic> strain increased the paralytic killing of <italic>C. elegans</italic> postulated to be caused by diverting glycine into HCN production, although the authors did not look at HCN production directly and saw no changes in expression of <italic>hcnABC</italic> genes (<xref ref-type="bibr" rid="B85">Sarwar et&#xa0;al., 2016</xref>). Our study shows the &#x394;<italic>gcvP2</italic> strain does indeed produce more HCN than the parent strain, confirming increased substrate availability can drive increases in <italic>hcnABC</italic> conversion of glycine to HCN. It is therefore surprising that we see cysteamine-mediated decreases in HCN production and reduced paralysis in <italic>C. elegans</italic>, (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>) and reduced virulence in the <italic>G. mellonella</italic> model (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>) despite inhibition of glycine catabolism.</p>
<p>Transcriptional control of <italic>hcnABC</italic>, which converts glycine into HCN and CO<sub>2</sub>, is complex (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>). HCN formation is greater under low oxygen tension and the anaerobic regulator of arginine deiminase and nitrate reductase (ANR) protein is one of a few transcriptional regulators which influence <italic>hcnABC</italic> (<xref ref-type="bibr" rid="B112">Zimmermann et&#xa0;al., 1991</xref>; <xref ref-type="bibr" rid="B54">Laville et&#xa0;al., 1998</xref>). ANR, and the <italic>E. coli</italic> homologue FNR, sense oxygen <italic>via</italic> an iron-sulfur cluster, and DNA binding is maximal under reducing conditions (<xref ref-type="bibr" rid="B110">Ye et&#xa0;al., 1995</xref>; <xref ref-type="bibr" rid="B55">Lazazzera et&#xa0;al., 1996</xref>), and iron availability also impacts HCN expression <italic>via</italic> ANR which is abolished in <italic>P. fluorescens</italic> when iron is depleted (<xref ref-type="bibr" rid="B6">Blumer and Haas, 2000</xref>). The quorum sensing response activators LasR and RhlR also regulate HCN production in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="B53">Latifi et&#xa0;al., 1995</xref>; <xref ref-type="bibr" rid="B106">Winson et&#xa0;al., 1995</xref>; <xref ref-type="bibr" rid="B83">Reimmann et&#xa0;al., 1997</xref>; <xref ref-type="bibr" rid="B103">Whiteley et&#xa0;al&#xb8;1999</xref>) and can act in concert to maximise HCN production (<xref ref-type="bibr" rid="B76">Pessi and Haas, 2000</xref>). The GacA two-component system <italic>via</italic> two regulatory RNAs, RsmZ and RsmY, also influences HCN expression indirectly <italic>via</italic> quorum sensing due to enhanced expression of <italic>rhlI</italic>, or directly post-transcriptionally, by enhancing the translation of <italic>hcnABC</italic> (<xref ref-type="bibr" rid="B77">Pessi and Haas, 2001</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>The effect of cysteamine on HCN production <bold>(A)</bold> provides clues to the anti-virulence activities of cysteamine. In untreated <italic>P. aeruginosa</italic> 1. Glycine cleavage is uninterrupted and normal levels of glycine are available as precursors for <italic>hcnABC</italic> gene cluster for the generation of HCN which is under varying levels of regulatory control by LasR, RhlR, AlgR, MvfR and ANR. In scenario 2. inactivation of glycine decarboxylase (GcvP2) prevents glycine utilisation, and higher concentrations of glycine are available for the synthesis of HCN by HcnABC and an increase of HCN is detected. In scenario 3. cysteamine reversibly inactivates GcvP2 <italic>via</italic> thiazolidine formation with the cofactor PLP. More glycine is available for HCN synthesis, but less HCN synthesis occurs, indicating cysteamine also impairs the regulation of one or more of the regulators listed above. Panel <bold>(B)</bold> summarises the anti-virulence activities reported in this manuscript.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-11-718213-g006.tif"/>
</fig>
<p>Therefore, we have uncovered that cysteamine blocks the glycine cleavage system and this should, in theory, increase HCN production as shown with the &#x394;<italic>gcvP2</italic> mutant. Instead, cysteamine must also simultaneously act upon one or more of the <italic>P. aeruginosa</italic> global regulatory systems to impair HCN production, despite the presumed backup of cellular glycine. These data highlight that precursor availability is a key cue in HCN production in <italic>P. aeruginosa</italic>, yet a cue which is still subordinate to the additional regulatory mechanisms detailed above. Thus, the dissection of a single, core metabolic target of cysteamine has unexpectedly shed light into the regulatory hierarchy of HCN production in <italic>P. aeruginosa</italic> &#x2013; a vital virulence factor in this organism.</p>
</sec>
<sec id="s4_2">
<title>Inhibition of Multiple Virulence Factors by Cysteamine</title>
<p>Quorum sensing systems coordinate the production of various virulence factors in <italic>P. aeruginosa</italic> including the production of phenazines. Our previous work demonstrated inhibition of pigment production in multiple <italic>P. aeruginosa</italic> strains and inhibition of the export of the pigment pyomelanin in <italic>B. cenocepacia</italic> strains (<xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>). Here we used the chloroform extraction method to confirm the dose-dependent reduction in pyocyanin production by <italic>P. aeruginosa</italic> in response to cysteamine. Similarly, cysteamine interferes with the production of the fluorescent, iron-chelating pyoverdine virulence factor. Pyoverdine production has been described as essential for virulence in <italic>in vivo</italic> models both with mutants of type strains (<xref ref-type="bibr" rid="B63">Meyer et&#xa0;al., 1996</xref>) and in CF isolates (<xref ref-type="bibr" rid="B45">Kang et&#xa0;al., 2019</xref>).</p>
<p>Anecdotal evidence from the CARE-CF-1 trial led us to also examine the effect of cysteamine on exopolysaccharide production. In the trial, a dominant pyomelanin-producing sputum isolate of <italic>P. aeruginosa</italic> was mucoid at day 0, (before treatment) and non-mucoid at day 14 following exposure to cysteamine. It is already known that the thiol, N-acetylcysteine (already used as a mucolytic treatment in CF), can reduce extracellular polysaccharide production in various bacteria (<xref ref-type="bibr" rid="B72">Olofsson et&#xa0;al., 2003</xref>). Cysteamine also demonstrated a significant, though modest, reduction in secreted exopolysaccharide produced by the mucoid alginate-producing NH57388A strain.</p>
<p>The anti-biofilm activity of cysteamine has been reported before. High concentrations can disrupt biofilms, whereas sub-MIC concentrations can prevent biofilms by <italic>P. aeruginosa</italic> and <italic>B. cepacia</italic> complex strains (<xref ref-type="bibr" rid="B12">Charrier et&#xa0;al., 2014</xref>; <xref ref-type="bibr" rid="B27">Fraser-Pitt et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B28">Fraser-Pitt et&#xa0;al., 2018</xref>). Here we demonstrate that concentrations of cysteamine that are therapeutically achievable <italic>via</italic> systemic dosing can also reduce the biofilm promoting activity of another agent, tobramycin. This antibiotic is frequently employed prophylactically in adults with CF known to be colonised with <italic>P. aeruginosa</italic> to suppress their growth, but sub-lethal concentrations of the antibiotic have long been known to encourage biofilm formation (<xref ref-type="bibr" rid="B39">Hoffman et&#xa0;al., 2005</xref>). A recent study (<xref ref-type="bibr" rid="B95">Tahrioui et&#xa0;al., 2019</xref>) demonstrated the adaptive response mechanism is thought to involve extracellular DNA release, PrrF small regulatory RNAs and quorum sensing <italic>via</italic> the pseudomonas quinolone signal (PQS).</p>
<p>The results above show cysteamine was capable of disrupting metabolism and a number of secreted virulence factors in <italic>P. aeruginosa.</italic> This was confirmed using the <italic>G. mellonella</italic> invertebrate model. Larvae melanised rapidly in response to <italic>P. aeruginosa</italic> NH57388A supernatants and died within 24 h. Cysteamine provided some protection against this toxic response and the results were evident quickly due to the effect on reducing melanisation at 1 h. Most deaths in the larvae injected with supernatants from treated <italic>P. aeruginosa</italic> occurred at 24 h with few thereafter indicating a protection from toxicity.</p>
<p>In conclusion, cysteamine inhibits glycine utilisation and dysregulates virulence factor production in <italic>P. aeruginosa</italic> at sub-inhibitory concentrations and reduces the secretion of toxic factors by <italic>P. aeruginosa</italic>. The strategic development of novel therapeutics which have anti-virulence properties and operate differently to conventional antibiotics has been described as essential for our progress in combating antimicrobial resistance (<xref ref-type="bibr" rid="B25">Fleitas Mart&#xed;nez et&#xa0;al., 2019</xref>). Compounds which can improve the effectiveness of other agents and at the same time reduce virulence factor production at sub-lethal concentrations are less likely to drive the emergence of resistance (<xref ref-type="bibr" rid="B99">Vale et&#xa0;al., 2016</xref>; <xref ref-type="bibr" rid="B67">Munguia and Nizet, 2017</xref>). As an endogenously produced molecule, expressed at sites of inflammation and infection, it maybe that cysteamine has an underappreciated role in innate defence against infection. In common with many innate immune effectors, it may work best in concert with other agents, particularly at therapeutic doses where the effects on individual virulence factors (except for the reduction in tobramycin mediated biofilm induction) are less easy to demonstrate. However, the ability to reduce several virulence factors at once in this versatile pathogen likely means the whole effect is greater than the sum of its parts. There is clearly more than one bacterial cell target for cysteamine and given the common effects on eukaryotic and prokaryotic glycine cleavage systems, cysteamine will affect both the host and the pathogen. Critical regulatory systems in <italic>P. aeruginosa</italic> are clearly disrupted by cysteamine and a systems-based approach may be useful in further understanding the impact of this aminothiol on microbial virulence and metabolism. The positive impact of cysteamine on several virulence factors in this still-common CF pathogen combined with the multivalent properties of this molecule (mucolysis, antibiotic-potentiation etc.) add to the potential utility for this endogenous molecule as a therapeutic in CF, and potentially beyond as we continue the search for agents to tackle the antimicrobial resistance crisis.</p>
</sec>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are publicly available. This data can be found here: [<uri xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD027156">https://www.ebi.ac.uk/pride/archive/projects/PXD027156</uri>].</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>DF-P is the corresponding author and wrote the original draft and submitted manuscript, had roles in supervision, conceptualisation, investigation, data curation and analysis of the project. SD made significant contributions to the conceptualisation of the project and was involved in investigation and analysis of data and reviewing/editing of the manuscript. DT-A is an investigating scientist and was involved in generating data and analysis and reviewing/editing. JH was involved in <italic>C. elegans</italic> investigation and data analysis. DS has made significant contributions to conceptualisation of the project and in <italic>G. mellonella</italic> method development. NL-R was a visiting student involved in investigation, data curation and analysis. PN was a visiting student involved in investigation, data curation and analysis. TS provided expertise for <italic>C. elegans</italic> method development and the review/editing of the manuscript. EM provided mass spectrometry expertise, and was involved in investigation and data generation. KM provided mass spectrometry expertise and was involved in investigation and data generation, reviewing/editing. NI supervised proteomics investigation. DM conceptualisation, review/editing. DO supervision, conceptualisation, review/editing. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>We would like to thank the Society for Applied Microbiology (Sfam) for funding the proteomics work contained in this manuscript <italic>via</italic> a New Lecturer Award (awarded to DF-P whilst a Lecturer at Edinburgh Napier University) in 2011. NL-R and PN had student placements at NovaBiotics Ltd and were generously supported by Equate Scotland Careerwise programme for women in STEM. SD was generously supported by a BBSRC Flexible Talent Mobility Account 2020-2021. All other work was commercially funded by NovaBiotics Ltd. NovaBiotics Ltd provided support in the form of salaries for authors DF-P, DT-A, JH, DS, DM, and DO.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>DF-P, DT-A, JH, DS, and DM are all employees of NovaBiotics Ltd. DAO is the CEO, CSO and a shareholder of NovaBiotics Ltd. DF-P and DO are authors of patent; WO2016198842A1, IL256162D0 - An amino thiol for use in the treatment of an infection caused by the bacterium mycobacterium spp. DO is also author of the following patents; US9364491B2 (and other territories) - Antimicrobial compositions with cysteamine/A composition comprising an antibiotic and a dispersant; WO2016046524A1 - Use of cysteamine in treating infections caused by yeasts/moulds; US9782423B2 (and other territories) - Antibiotic compositions comprising an antibiotic agent and cysteamine; US9339525B2 (and other territories) - Inhibition of biofilm organisms; and US20190175501A1 pending (and other territories) - Microparticles comprising a sulphur-containing compound. This does not alter our adherence to Frontiers policies on sharing data and materials.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec id="s10" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2021.718213/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcimb.2021.718213/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.tif" id="SF1" mimetype="image/tiff"/>
<supplementary-material xlink:href="Table_1.docx" id="ST1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
<supplementary-material xlink:href="Table_2.docx" id="ST2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>Iannuzzi</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>Z.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Mdab From Escherichia Coli: Cloning, Purification, Crystallization and Preliminary X-Ray Analysis</article-title>. <source>Acta Crystallogr. Sect. F Struct. Biol. Cryst Commun.</source> <volume>61</volume> (<issue>Pt 2</issue>), <fpage>235</fpage>&#x2013;<lpage>238</lpage>. doi: <pub-id pub-id-type="doi">10.1107/S1744309105001545</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amikam</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Galperin</surname> <given-names>M. Y.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Pilz Domain is Part of the Bacterial C-Di-GMP Binding Protein</article-title>. <source>Bioinformatics</source> <volume>22</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bti739</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armirotti</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Tomati</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Matthes</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Veit</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Cholon</surname> <given-names>D. M.</given-names>
</name>
<name>
<surname>Phuan</surname> <given-names>P. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity</article-title>. <source>Sci. Rep.</source> <volume>9</volume> (<issue>1</issue>), <fpage>10310</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-46639-1</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azam</surname> <given-names>M. W.</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>A. U.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Updates on the Pathogenicity Status of Pseudomonas Aeruginosa</article-title>. <source>Drug Discov Today</source> <volume>24</volume> (<issue>1</issue>), <fpage>350</fpage>&#x2013;<lpage>359</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drudis.2018.07.003</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasi</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Carnovale</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Cimino</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Lucidi</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Salvatore</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Messore</surname> <given-names>B.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Treatment Compliance in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Infection Treated With Tobramycin Inhalation Powder: The FREE Study</article-title>. <source>Respir. Med.</source> <volume>138</volume>, <fpage>88</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rmed.2018.03.034</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blumer</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Iron Regulation of the Hcnabc Genes Encoding Hydrogen Cyanide Synthase Depends on the Anaerobic Regulator ANR Rather Than on the Global Activator Gaca in Pseudomonas Fluorescens CHA0</article-title>. <source>Microbiol. (Reading)</source> <volume>146</volume> (<issue>Pt 10</issue>), <fpage>2417</fpage>&#x2013;<lpage>2424</lpage>. doi: <pub-id pub-id-type="doi">10.1099/00221287-146-10-2417</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buell</surname> <given-names>M. V.</given-names>
</name>
<name>
<surname>Hansen</surname> <given-names>R. E.</given-names>
</name>
</person-group> (<year>1960</year>). <article-title>Reaction of Pyridoxal-5-Phosphate With Aminothiols</article-title>. <source>J. Am. Chem. Soc.</source> <volume>82</volume> (<issue>23</issue>), <fpage>6042</fpage>&#x2013;<lpage>6049</lpage>. doi: <pub-id pub-id-type="doi">10.1021/ja01508a018</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname> <given-names>K. E.</given-names>
</name>
<name>
<surname>Lainson</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Imrie</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Fraser-Pitt</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Yaga</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>D. G.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Performance of Five Different Electrospray Ionisation Sources in Conjunction With Rapid Monolithic Column Liquid Chromatography and Fast MS/MS Scanning</article-title>. <source>Proteomics</source> <volume>9</volume> (<issue>6</issue>), <fpage>1720</fpage>&#x2013;<lpage>1726</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pmic.200800200</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buyck</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Plesiat</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Traore</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Vanderbist</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Tulkens</surname> <given-names>P. M.</given-names>
</name>
<name>
<surname>Van Bambeke</surname> <given-names>F</given-names>
</name>
</person-group>. (<year>2012</year>). <article-title>Increased Susceptibility of Pseudomonas Aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of Oprm and Increased Outer-Membrane Permeability</article-title>. <source>Clin. Infect. Dis.</source> <volume>55</volume>, <fpage>534</fpage>&#x2013;<lpage>542</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/cis473</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castric</surname> <given-names>K. F.</given-names>
</name>
<name>
<surname>Castric</surname> <given-names>P. A.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Method for Detection of Cyanogenic Bacteria</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>45</volume>, <fpage>701</fpage>&#x2013;<lpage>702</lpage>. doi: <pub-id pub-id-type="doi">10.1128/aem.45.2.701-702.1983</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamrad</surname> <given-names>D. C.</given-names>
</name>
<name>
<surname>Koerting</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Gobom</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Thiele</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Klose</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>H. E.</given-names>
</name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Interpretation of Mass Spectrometry Data for High-Throughput Proteomics</article-title>. <source>Anal. Bioanal Chem.</source> <volume>376</volume> (<issue>7</issue>), <fpage>1014</fpage>&#x2013;<lpage>1022</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00216-003-1995-x</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charrier</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Rodger</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kowalczuk</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Shand</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Fraser-Pitt</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Cysteamine (Lynovex<sup>&#xae;</sup>), a Novel Mucoactive Antimicrobial &amp; Antibiofilm Agent for the Treatment of Cystic Fibrosis</article-title>. <source>Orphanet J. Rare Dis.</source> <volume>9</volume>, <fpage>189</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13023-014-0189-2</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname> <given-names>I. Y.</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>K. B.</given-names>
</name>
<name>
<surname>Heo</surname> <given-names>Y. J.</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>Y. H.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Effect of PEL Exopolysaccharide on the Wspf Mutant Phenotypes in Pseudomonas Aeruginosa PA14</article-title>. <source>J. Microbiol. Biotechnol.</source> <volume>18</volume> (<issue>7</issue>), <fpage>1227</fpage>&#x2013;<lpage>1234</lpage>.</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullen</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Weiser</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Olszak</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Maldonado</surname> <given-names>R. F.</given-names>
</name>
<name>
<surname>Moreira</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Slachmuylders</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Phenotypic Characterization of an International Pseudomonas Aeruginosa Reference Panel: Strains of Cystic Fibrosis (CF) Origin Show Less <italic>In Vivo</italic> Virulence Than Non-CF Strains</article-title>. <source>Microbiol. (Reading)</source> <volume>161</volume> (<issue>10</issue>), <fpage>1961</fpage>&#x2013;<lpage>1977</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.000155</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Cystic Fibrosis Foundation Patient Registry</collab>
</person-group>. (<year>2019</year>). <article-title>2018 Annual Data Report</article-title> (<publisher-name>Cystic Fibrosis Foundation</publisher-name>). Available at: <uri xlink:href="https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf">https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf</uri> (Accessed <access-date>April 2021</access-date>).</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darby</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Cosma</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>J. H.</given-names>
</name>
<name>
<surname>Manoil</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Lethal Paralysis of Caenorhabditis Elegans by Pseudomonas Aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U.&#xa0;S. A.</source> <volume>96</volume> (<issue>26</issue>), <fpage>15202</fpage>&#x2013;<lpage>15207</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.26.15202</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Marco</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Coletta</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bombardieri</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>1965</year>). <article-title>Inhibition of Plasma Monoamine Oxidase by Cysteamine</article-title>. <source>Nature</source> <volume>205</volume>, <fpage>176</fpage>. doi: <pub-id pub-id-type="doi">10.1038/205176a0</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Stefano</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Villella</surname> <given-names>V. R.</given-names>
</name>
<name>
<surname>Esposito</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Tosco</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sepe</surname> <given-names>A.</given-names>
</name>
<name>
<surname>De Gregorio</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Restoration of CFTR Function in Patients With Cystic Fibrosis Carrying the F508del-CFTR Mutation</article-title>. <source>Autophagy</source> <volume>10</volume> (<issue>11</issue>), <fpage>2053</fpage>&#x2013;<lpage>2074</lpage>. doi: <pub-id pub-id-type="doi">10.4161/15548627.2014.973737</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devereux</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Fraser-Pitt</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Devlin</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Mercer</surname> <given-names>D.</given-names>
</name>
<name>
<surname>O&#x2019;Neil</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-Based Ex Vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum</article-title>. <source>EBiomedicine</source> <volume>2</volume> (<issue>10</issue>), <fpage>1507</fpage>&#x2013;<lpage>1512</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.018</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devereux</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Wrolstad</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Bourke</surname> <given-names>S. J.</given-names>
</name>
<name>
<surname>Daines</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Doe</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Dougherty</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Oral Cysteamine as an Adjunct Treatment in Cystic Fibrosis Pulmonary Exacerbations: An Exploratory Randomized Clinical Trial</article-title>. <source>PloS One</source> <volume>15</volume> (<issue>12</issue>), <fpage>e0242945</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0242945</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolan</surname> <given-names>S. K.</given-names>
</name>
<name>
<surname>Kohlstedt</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Trigg</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Vallejo Ramirez</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Kaminski</surname> <given-names>C. F.</given-names>
</name>
<name>
<surname>Wittmann</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Contextual Flexibility in Pseudomonas Aeruginosa Central Carbon Metabolism During Growth in Single Carbon Sources</article-title>. <source>mBio</source> <volume>11</volume> (<issue>2</issue>), <fpage>e02684</fpage>&#x2013;<lpage>e02619</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.02684-19</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Hoffman</surname> <given-names>L. R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Exploratory Study of the Prevalence and Clinical Significance of Tobramycin-Mediated Biofilm Induction in Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>54</volume> (<issue>7</issue>), <fpage>3024</fpage>&#x2013;<lpage>3026</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.00102-10</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Essar</surname> <given-names>D. W.</given-names>
</name>
<name>
<surname>Eberly</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Hadero</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Crawford</surname> <given-names>I. P.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Identification and Characterization of Genes for a Second Anthranilate Synthase in Pseudomonas Aeruginosa: Interchangeability of the Two Anthranilate Synthases and Evolutionary Implications</article-title>. <source>J. Bacteriol.</source> <volume>172</volume> (<issue>2</issue>), <fpage>884</fpage>&#x2013;<lpage>900</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jb.172.2.884-900.1990</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrari</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Monzani</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Villella</surname> <given-names>V. R.</given-names>
</name>
<name>
<surname>Esposito</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Saluzzo</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Rossin</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Cysteamine Re-Establishes the Clearance of Pseudomonas Aeruginosa by Macrophages Bearing the Cystic Fibrosis-Relevant F508del-CFTR Mutation</article-title>. <source>Cell Death Dis.</source> <volume>8</volume> (<issue>1</issue>), <fpage>e2544</fpage>. doi: <pub-id pub-id-type="doi">10.1038/cddis.2016.476</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleitas Mart&#xed;nez</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Cardoso</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Ribeiro</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Franco</surname> <given-names>O. L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Recent Advances in Anti-Virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>9</volume>, <elocation-id>74</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2019.00074</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser-Pitt</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Mercer</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>What Role for Cysteamine in the Defence Against Infection</article-title>? <source>Emerg. Top. Life Sci.</source> <fpage>ETLS20200351</fpage>. doi: <pub-id pub-id-type="doi">10.1042/ETLS20200351</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser-Pitt</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Mercer</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Lovie</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>J.</given-names>
</name>
<name>
<surname>O&#x2019;Neil</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Activity of Cysteamine Against the Cystic Fibrosis Pathogen Burkholderia Cepacia Complex</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>60</volume> (<issue>10</issue>), <fpage>6200</fpage>&#x2013;<lpage>6206</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01198-16</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser-Pitt</surname> <given-names>D. J.</given-names>
</name>
<name>
<surname>Mercer</surname> <given-names>D. K.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Kowalczuk</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Lovie</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas Aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics Against Bacterial Infection</article-title>. <source>Infect. Immun.</source> <volume>86</volume> (<issue>6</issue>), <fpage>e00947</fpage>&#x2013;<lpage>e00917</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00947-17</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geller</surname> <given-names>D. E.</given-names>
</name>
<name>
<surname>Weers</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Heuerding</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Development of an Inhaled Dry-Powder Formulation of Tobramycin Using Pulmosphere&#x2122; Technology</article-title>. <source>J.&#xa0;Aerosol Med. Pulm Drug Deliv.</source> <volume>24</volume> (<issue>4</issue>), <fpage>175</fpage>&#x2013;<lpage>182</lpage>. doi: <pub-id pub-id-type="doi">10.1089/jamp.2010.0855</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghafoor</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hay</surname> <given-names>I. D.</given-names>
</name>
<name>
<surname>Rehm</surname> <given-names>B. H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Role of Exopolysaccharides in Pseudomonas Aeruginosa Biofilm Formation and Architecture</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>77</volume> (<issue>15</issue>), <fpage>5238</fpage>&#x2013;<lpage>5246</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.00637-11</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname> <given-names>R. L.</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Ramsey</surname> <given-names>B. W.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>168</volume>, <fpage>918</fpage>&#x2013;<lpage>951</lpage>. doi: <pub-id pub-id-type="doi">10.1164/rccm.200304-505SO</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilchrist</surname> <given-names>F. J.</given-names>
</name>
<name>
<surname>Bright-Thomas</surname> <given-names>R. J.</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Span&#x11b;l</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Webb</surname> <given-names>A. K.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Hydrogen Cyanide Concentrations in the Breath of Adult Cystic Fibrosis Patients With and Without <italic>Pseudomonas aeruginosa </italic> Infection</article-title>. <source>J. Breath Res.</source> <volume>7</volume> (<issue>2</issue>), <fpage>026010</fpage>.</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilchrist</surname> <given-names>F. J.</given-names>
</name>
<name>
<surname>Belcher</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>A. M.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Smyth</surname> <given-names>A. R.</given-names>
</name>
<name>
<surname>Southern</surname> <given-names>K. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Exhaled Breath Hydrogen Cyanide as a Marker of Early Pseudomonas Aeruginosa Infection in Children With Cystic Fibrosis</article-title>. <source>ERJ Open Res.</source> <volume>1</volume> (<issue>2</issue>), <fpage>00044</fpage>&#x2013;<lpage>02015</lpage>. doi: <pub-id pub-id-type="doi">10.1183/23120541.00044-2015</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gj&#xf8;dsbol</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Christiensen</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Karlsmark</surname> <given-names>T.</given-names>
</name>
<name>
<surname>J&#xf8;rgensen</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>B. M.</given-names>
</name>
<name>
<surname>Krogfelt</surname> <given-names>K. A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Multiple Bacterial Species Reside in Chronic Wounds: A Longitudinal Study</article-title>. <source>Int. Wound J.</source> <volume>3</volume>, <fpage>225</fpage>&#x2013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1742-481X.2006.00159.x</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayasaka</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Tada</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Effects of the Metabolites of the Branched-Chain Amino Acids and Cysteamine on the Glycine Cleavage System</article-title>. <source>Biochem. Int.</source> <volume>6</volume> (<issue>2</issue>), <fpage>225</fpage>&#x2013;<lpage>230</lpage>.</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Baldini</surname> <given-names>R. L.</given-names>
</name>
<name>
<surname>D&#xe9;ziel</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Saucier</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Liberati</surname> <given-names>N. T.</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>). <article-title>The Broad Host Range Pathogen Pseudomonas Aeruginosa Strain PA14 Carries Two Pathogenicity Islands Harboring Plant and Animal Virulence Genes</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>101</volume> (<issue>8</issue>), <fpage>2530</fpage>&#x2013;<lpage>2535</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0304622101</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heeb</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Fletcher</surname> <given-names>M. P.</given-names>
</name>
<name>
<surname>Chhabra</surname> <given-names>S. R.</given-names>
</name>
<name>
<surname>Diggle</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Camara</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Quinolones: From Antibiotics to Autoinducers</article-title>. <source>FEMS Microbiol. Rev.</source> <volume>35</volume>, <fpage>247</fpage>&#x2013;<lpage>274</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00247.x</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hickman</surname> <given-names>J. W.</given-names>
</name>
<name>
<surname>Tifrea</surname> <given-names>D. F.</given-names>
</name>
<name>
<surname>Harwood</surname> <given-names>C. S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>A Chemosensory System That Regulates Biofilm Formation Through Modulation of Cyclic Diguanylate Levels</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>102</volume> (<issue>40</issue>), <fpage>14422</fpage>&#x2013;<lpage>14427</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0507170102</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffman</surname> <given-names>L. R.</given-names>
</name>
<name>
<surname>D&#x2019;Argenio</surname> <given-names>D. A.</given-names>
</name>
<name>
<surname>MacCoss</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>R. A.</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>S. I.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Aminoglycoside Antibiotics Induce Bacterial Biofilm Formation</article-title>. <source>Nature</source> <volume>436</volume> (<issue>7054</issue>), <fpage>1171</fpage>&#x2013;<lpage>1175</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.73.4.2504-2514.2005</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Rasmussen</surname> <given-names>T. B.</given-names>
</name>
<name>
<surname>Jensen</surname> <given-names>P&#xd8;</given-names>
</name>
<name>
<surname>Stub</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Hentzer</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Molin</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Novel Mouse Model of Chronic Pseudomonas Aeruginosa Lung Infection Mimicking Cystic Fibrosis</article-title>. <source>Infect. Immun.</source> <volume>73</volume> (<issue>4</issue>), <fpage>2504</fpage>&#x2013;<lpage>2514</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.73.4.2504-2514.2005</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holloway</surname> <given-names>B. W.</given-names>
</name>
</person-group> (<year>1955</year>). <article-title>Genetic Recombination in Pseudomonas Aeruginosa</article-title>. <source>J.&#xa0;Gen. Microbiol.</source> <volume>13</volume>, <fpage>572</fpage>&#x2013;<lpage>581</lpage>. doi: <pub-id pub-id-type="doi">10.1099/00221287-13-3-572</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Wilks</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A Rapid Seamless Method for Gene Knockout in Pseudomonas Aeruginosa</article-title>. <source>BMC Microbiol.</source> <volume>17</volume> (<issue>1</issue>), <fpage>199</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12866-017-1112-5</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwama</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kure</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Narisawa</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Tada</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>1997</year>). <article-title>Depletion of Cerebral D-Serine in non-Ketotic Hyperglycinemia: Possible Involvement of Glycine Cleavage System in Control of Endogenous D-Serine</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>231</volume> (<issue>3</issue>), <fpage>793</fpage>&#x2013;<lpage>796</lpage>. doi: <pub-id pub-id-type="doi">10.1006/bbrc.1997.6184</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jander</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Rahme</surname> <given-names>L. G.</given-names>
</name>
<name>
<surname>Ausubel</surname> <given-names>F. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Positive Correlation Between Virulence of Pseudomonas Aeruginosa Mutants in Mice and Insects</article-title>. <source>J.&#xa0;Bacteriol.</source> <volume>182</volume> (<issue>13</issue>), <fpage>3843</fpage>&#x2013;<lpage>3845</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.182.13.3843-3845.2000</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Revtovich</surname> <given-names>A. V.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>K. N.</given-names>
</name>
<name>
<surname>Cannon</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Kirienko</surname> <given-names>N. V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Pyoverdine-Dependent Virulence of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients</article-title>. <source>Front. Microbiol.</source> <volume>10</volume>, <elocation-id>2048</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2019.02048</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Edwards</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Dixon</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Galleria Mellonella Infection Model Identifies Both High and Low Lethality of Clostridium Perfringens Toxigenic Strains and Their Response to Antimicrobials</article-title>. <source>Front. Microbiol.</source> <volume>10</volume>, <elocation-id>1281</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2019.01281</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerem</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Viviani</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zolin</surname> <given-names>A.</given-names>
</name>
<name>
<surname>MacNeill</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hatziagorou</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Ellemunter</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Factors Associated With FEV1 Decline in Cystic Fibrosis: Analysis of the ECFS Patient Registry</article-title>. <source>Eur. Respir. J.</source> <volume>43</volume> (<issue>1</issue>), <fpage>125</fpage>&#x2013;<lpage>133</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00166412</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Lydecker</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Dav&#xe9;</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bork</surname> <given-names>J. T.</given-names>
</name>
<name>
<surname>Roghmann</surname> <given-names>M. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Diabetic Foot Infections: Local Prevalence of and Case-Control Study of Risk Factors for Methicillin-Resistant Staphylococcus Aureus and Pseudomonas Aeruginosa</article-title>. <source>Open Forum Infect. Dis.</source> <volume>7</volume> (<issue>10</issue>), <fpage>ofaa412</fpage>. doi: <pub-id pub-id-type="doi">10.1093/ofid/ofaa412</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konstan</surname> <given-names>M. W.</given-names>
</name>
<name>
<surname>Flume</surname> <given-names>P. A.</given-names>
</name>
<name>
<surname>Kappler</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Chiron</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Higgins</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Brockhaus</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Safety, Efficacy and Convenience of Tobramycin Inhalation Powder in Cystic Fibrosis Patients: The EAGER Trial</article-title>. <source>J. Cyst. Fibros.</source> <volume>10</volume> (<issue>1</issue>), <fpage>54</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcf.2010.10.003</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostylev</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>D. Y.</given-names>
</name>
<name>
<surname>Smalley</surname> <given-names>N. E.</given-names>
</name>
<name>
<surname>Salukhe</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Greenberg</surname> <given-names>E. P.</given-names>
</name>
<name>
<surname>Dandekar</surname> <given-names>A. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Evolution of the Pseudomonas Aeruginosa Quorum-Sensing Hierarchy</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>116</volume> (<issue>14</issue>), <fpage>7027</fpage>&#x2013;<lpage>7032</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1819796116</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koulenti</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Lisboa</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Brun-Buisson</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Krueger</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Macor</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sole-Violan</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>EU-VAP/CAP Study Group. Spectrum of Practice in the Diagnosis of Nosocomial Pneumonia in Patients Requiring Mechanical Ventilation in European Intensive Care Units</article-title>. <source>Crit. Care Med.</source> <volume>37</volume> (<issue>8</issue>), <fpage>2360</fpage>&#x2013;<lpage>2368</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181a037ac</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurachi</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>1958</year>). <article-title>Studies on the Biosynthesis of Pyocyanine (II): Isolation and Determination of Pyocyanine</article-title>. <source>Bull. Inst. Chem. Res.</source> <volume>36</volume> (<issue>6</issue>), <fpage>174</fpage>&#x2013;<lpage>187</lpage>.</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latifi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Winson</surname> <given-names>M. K.</given-names>
</name>
<name>
<surname>Foglino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Bycroft</surname> <given-names>B. W.</given-names>
</name>
<name>
<surname>Stewart</surname> <given-names>G. S.</given-names>
</name>
<name>
<surname>Lazdunski</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>1995</year>). <article-title>Multiple Homologues of Luxr and Luxi Control Expression of Virulence Determinants and Secondary Metabolites Through Quorum Sensing in Pseudomonas Aeruginosa PAO1</article-title>. <source>Mol. Microbiol.</source> <volume>17</volume> (<issue>2</issue>), <fpage>333</fpage>&#x2013;<lpage>343</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2958.1995.mmi_17020333.x</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laville</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Blumer</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Von Schroetter</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Gaia</surname> <given-names>V.</given-names>
</name>
<name>
<surname>D&#xe9;fago</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Keel</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>1998</year>). <article-title>Characterization of the Hcnabc Gene Cluster Encoding Hydrogen Cyanide Synthase and Anaerobic Regulation by ANR in the Strictly Aerobic Biocontrol Agent Pseudomonas Fluorescens CHA0</article-title>. <source>J. Bacteriol.</source> <volume>180</volume> (<issue>12</issue>), <fpage>3187</fpage>&#x2013;<lpage>3196</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.180.12.3187-3196.1998</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazazzera</surname> <given-names>B. A.</given-names>
</name>
<name>
<surname>Beinert</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Khoroshilova</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Kennedy</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Kiley</surname> <given-names>P. J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>DNA Binding and Dimerization of the Fe-s-Containing FNR Protein From Escherichia Coli Are Regulated by Oxygen</article-title>. <source>J. Biol. Chem.</source> <volume>271</volume> (<issue>5</issue>), <fpage>2762</fpage>&#x2013;<lpage>2768</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.271.5.2762</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>V. T.</given-names>
</name>
<name>
<surname>Matewish</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Kessler</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Hyodo</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hayakawa</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Lory</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>A Cyclic-Di-GMP Receptor Required for Bacterial Exopolysaccharide Production</article-title>. <source>Mol. Microbiol.</source> <volume>65</volume> (<issue>6</issue>), <fpage>1474</fpage>&#x2013;<lpage>1484</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05879.x</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd</surname> <given-names>M. G.</given-names>
</name>
<name>
<surname>Lundgren</surname> <given-names>B. R.</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>C. W.</given-names>
</name>
<name>
<surname>Gagnon</surname> <given-names>L. B.</given-names>
</name>
<name>
<surname>Mah</surname> <given-names>T. F.</given-names>
</name>
<name>
<surname>Moffat</surname> <given-names>J. F.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Targeting the Alternative Sigma Factor Rpon to Combat Virulence in Pseudomonas Aeruginosa</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>12615</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-12667-y</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowry</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>M. S.</given-names>
</name>
<name>
<surname>Brosnan</surname> <given-names>J. T.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Specificity and Mechanism of the Inhibition by Cysteamine of the Renal Glycine-Cleavage Complex</article-title>. <source>Biochem. Soc Trans.</source> <volume>14</volume>, <fpage>131</fpage>&#x2013;<lpage> 132</lpage>. doi: <pub-id pub-id-type="doi">10.1042/bst0140131</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lundgren</surname> <given-names>B. R.</given-names>
</name>
<name>
<surname>Thornton</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Dornan</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Villegas-Pe&#xf1;aranda</surname> <given-names>L. R.</given-names>
</name>
<name>
<surname>Boddy</surname> <given-names>C. N.</given-names>
</name>
<name>
<surname>Nomura</surname> <given-names>C. T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Gene PA2449 is Essential for Glycine Metabolism and Pyocyanin Biosynthesis in Pseudomonas Aeruginosa PAO1</article-title>. <source>J.&#xa0;Bacteriol.</source> <volume>195</volume> (<issue>9</issue>), <fpage>2087</fpage>&#x2013;<lpage>2100</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.02205-12</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyczak</surname> <given-names>J. B.</given-names>
</name>
<name>
<surname>Cannon</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Pier</surname> <given-names>G. B.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Establishment of Pseudomonas Aeruginosa Infection: Lessons From a Versatile Opportunist</article-title>. <source>Microbes Infect.</source> <volume>2</volume>, <fpage>1051</fpage>&#x2013;<lpage>1060</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1286-4579(00)01259-4</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGrath</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wade</surname> <given-names>D. S.</given-names>
</name>
<name>
<surname>Pesci</surname> <given-names>E. C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Dueling Quorum Sensing Systems in Pseudomonas Aeruginosa Control the Production of the Pseudomonas Quinolone Signal (PQS)</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>230</volume>, <fpage>27</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0378-1097(03)00849-8</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merighi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>V. T.</given-names>
</name>
<name>
<surname>Hyodo</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hayakawa</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Lory</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The Second Messenger Bis-(3&#x2019;-5&#x2019;)-Cyclic-GMP and its Pilz Domain-Containing Receptor Alg44 Are Required for Alginate Biosynthesis in Pseudomonas Aeruginosa</article-title>. <source>Mol. Microbiol.</source> <volume>65</volume> (<issue>4</issue>), <fpage>876</fpage>&#x2013;<lpage>895</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05817.x</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Neely</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Stintzi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Georges</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Holder</surname> <given-names>I. A.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Pyoverdin Is Essential for Virulence of Pseudomonas Aeruginosa</article-title>. <source>Infect. Immun.</source> <volume>64</volume> (<issue>2</issue>), <fpage>518</fpage>&#x2013;<lpage>523</lpage>. doi: <pub-id pub-id-type="doi">10.1128/iai.64.2.518-523.1996</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Middleton</surname> <given-names>P. G.</given-names>
</name>
<name>
<surname>Mall</surname> <given-names>M. A.</given-names>
</name>
<name>
<surname>D&#x159;ev&#xed;nek</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Lands</surname> <given-names>L. C.</given-names>
</name>
<name>
<surname>McKone</surname> <given-names>E. F.</given-names>
</name>
<name>
<surname>Polineni</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis With a Single Phe508del Allele</article-title>. <source>N. Engl. J. Med.</source> <volume>381</volume> (<issue>19</issue>), <fpage>1809</fpage>&#x2013;<lpage>1819</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1908639</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Miller</surname> <given-names>J. H.</given-names>
</name>
</person-group> (<year>1972</year>). <source>Experiments in Molecular Genetics</source> (<publisher-loc>Cold Spring Harbor, NY</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory</publisher-name>).</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mowat</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Paterson</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Fothergill</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>E. A.</given-names>
</name>
<name>
<surname>Ledson</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Walshaw</surname> <given-names>M. J.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Pseudomonas Aeruginosa Population Diversity and Turnover in Cystic Fibrosis Chronic Infections</article-title>. <source>Am. J. Respir. Crit. Care Med.</source> <volume>183</volume>, <fpage>1674</fpage>&#x2013;<lpage>1679</lpage>. doi: <pub-id pub-id-type="doi">10.1164/rccm.201009-1430OC</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munguia</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Nizet</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>38</volume> (<issue>5</issue>), <fpage>473</fpage>&#x2013;<lpage>488</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tips.2017.02.003</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nathwani</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Raman</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Sulham</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Gavaghan</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Menon</surname> <given-names>V.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Clinical and Economic Consequences of Hospital-Acquired Resistant and Multidrug-Resistant Pseudomonas Aeruginosa Infections: A Systematic Review and Meta-Analysis</article-title>. <source>Antimicrob. Resist. Infect. Control</source> <volume>3</volume>, <elocation-id>32</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/2047-2994-3-32</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicastro</surname> <given-names>G. G.</given-names>
</name>
<name>
<surname>Kaihami</surname> <given-names>G. H.</given-names>
</name>
<name>
<surname>Pereira</surname> <given-names>T. O.</given-names>
</name>
<name>
<surname>Meireles</surname> <given-names>D. A.</given-names>
</name>
<name>
<surname>Groleau</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>D&#xe9;ziel</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Cyclic-Di-GMP Levels Affect Pseudomonas Aeruginosa Fitness in the Presence of Imipenem</article-title>. <source>Environ. Microbiol.</source> <volume>16</volume> (<issue>5</issue>), <fpage>1321</fpage>&#x2013;<lpage>1333</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1462-2920.12422</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norman</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Ciofu</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Amador</surname> <given-names>C. I.</given-names>
</name>
<name>
<surname>H&#xf8;iby</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Jelsbak</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Genome Sequence of Pseudomonas Aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate</article-title>. <source>Genome Announc.</source> <volume>4</volume> (<issue>1</issue>), <fpage>e00008</fpage>&#x2013;<lpage>e00016</lpage>. doi: <pub-id pub-id-type="doi">10.1128/genomeA.00008-16</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oglesby</surname> <given-names>L. L.</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ohman</surname> <given-names>D. E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Membrane Topology and Roles of Pseudomonas Aeruginosa Alg8 and Alg44 in Alginate Polymerization</article-title>. <source>Microbiol. (Reading)</source> <volume>154</volume> (<issue>Pt 6</issue>), <fpage>1605</fpage>&#x2013;<lpage>1615</lpage>. doi: <pub-id pub-id-type="doi">10.1099/mic.0.2007/015305-0</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olofsson</surname> <given-names>A. C.</given-names>
</name>
<name>
<surname>Hermansson</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Elwing</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>N-Acetyl-L-Cysteine Affects Growth, Extracellular Polysaccharide Production, and Bacterial Biofilm Formation on Solid Surfaces</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>69</volume> (<issue>8</issue>), <fpage>4814</fpage>&#x2013;<lpage>4822</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.69.8.4814-4822.2003</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Toole</surname> <given-names>G. A.</given-names>
</name>
<name>
<surname>Pratt</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Watnick</surname> <given-names>P. I.</given-names>
</name>
<name>
<surname>Newman</surname> <given-names>D. K.</given-names>
</name>
<name>
<surname>Weaver</surname> <given-names>V. B.</given-names>
</name>
<name>
<surname>Kolter</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Genetic Approaches to Study of Biofilms</article-title>. <source>Methods Enzymol.</source> <volume>310</volume>, <fpage>91</fpage>&#x2013;<lpage>109</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0076-6879(99)10008-9</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parales</surname> <given-names>R. E.</given-names>
</name>
<name>
<surname>Ditty</surname> <given-names>J. L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Chemotaxis to Atypical Chemoattractants by Soil Bacteria</article-title>. <source>Methods Mol. Biol.</source> <volume>1729</volume>, <fpage>255</fpage>&#x2013;<lpage>280</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4939-7577-8_21</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pesci</surname> <given-names>E. C.</given-names>
</name>
<name>
<surname>Millbank</surname> <given-names>J. B.</given-names>
</name>
<name>
<surname>Pearson</surname> <given-names>P.</given-names>
</name>
<name>
<surname>McKnight</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kende</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Greenberg</surname> <given-names>E. P.</given-names>
</name>
<etal/>
</person-group>. (<year>1999</year>). <article-title>Quinolone Signaling in the Cell-to-Cell Communication System of Pseudomonas Aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>96</volume>, <fpage>11229</fpage>&#x2013;<lpage>11234</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.20.11229</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pessi</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Transcriptional Control of the Hydrogen Cyanide Biosynthetic Genes Hcnabc by the Anaerobic Regulator ANR and the Quorum-Sensing Regulators Lasr and Rhlr in Pseudomonas Aeruginosa</article-title>. <source>J.&#xa0;Bacteriol.</source> <volume>182</volume> (<issue>24</issue>), <fpage>6940</fpage>&#x2013;<lpage>6949</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.182.24.6940-6949.2000</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pessi</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Dual Control of Hydrogen Cyanide Biosynthesis by the Global Activator Gaca in Pseudomonas Aeruginosa PAO1</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>200</volume> (<issue>1</issue>), <fpage>73</fpage>&#x2013;<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1574-6968.2001.tb10695.x</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitari</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Malergue</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Philippe</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Massucci</surname> <given-names>M. T.</given-names>
</name>
<name>
<surname>Chabret</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>Pantetheinase Activity of Membrane-Bound Vanin-1: Lack of Free Cysteamine in Tissues of Vanin-1 Deficient Mice</article-title>. <source>FEBS Lett.</source> <volume>483</volume> (<issue>2-3</issue>), <fpage>149</fpage>&#x2013;<lpage>154</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0014-5793(00)02110-4</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poudyal</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Sauer</surname> <given-names>K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The ABC of Biofilm Drug Tolerance: The Merr-Like Regulator Brlr is an Activator of ABC Transport Systems, With PA1874-77 Contributing to the Tolerance of Pseudomonas Aeruginosa Biofilms to Tobramycin</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>62</volume> (<issue>2</issue>), <fpage>e01981</fpage>&#x2013;<lpage>e01917</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01981-17</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Wood</surname> <given-names>T. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Serine Hydroxymethyltransferase Shra (PA2444) Controls Rugose Small-Colony Variant Formation in Pseudomonas Aeruginosa</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <elocation-id>315</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2018.00315</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahme</surname> <given-names>L. G.</given-names>
</name>
<name>
<surname>Stevens</surname> <given-names>E. J.</given-names>
</name>
<name>
<surname>Wolfort</surname> <given-names>S. F.</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Tompkins</surname> <given-names>R. G.</given-names>
</name>
<name>
<surname>Ausubel</surname> <given-names>F. M.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Common Virulence Factors for Bacterial Pathogenicity in Plants and Animals</article-title>. <source>Science</source> <volume>268</volume> (<issue>5219</issue>), <fpage>1899</fpage>&#x2013;<lpage>1902</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.7604262</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramus</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>1977</year>). <article-title>Alcian Blue: A Quantitative Aqueous Assay for Algal Acid and Sulfated Polysaccharides</article-title>. <source>J. Phycol.</source> <volume>13</volume>, <fpage>345</fpage>&#x2013;<lpage>348</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1529-8817.1977.tb02939.x</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reimmann</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Beyeler</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Latifi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Winteler</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Foglino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lazdunski</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>1997</year>). <article-title>The Global Activator Gaca of Pseudomonas Aeruginosa PAO Positively Controls the Production of the Autoinducer N-Butyryl-Homoserine Lactone and the Formation of the Virulence Factors Pyocyanin, Cyanide, and Lipase</article-title>. <source>Mol. Microbiol.</source> <volume>24</volume> (<issue>2</issue>), <fpage>309</fpage>&#x2013;<lpage>319</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2958.1997.3291701.x</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryall</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Davies</surname> <given-names>J. C.</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Shoemark</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>H. D.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Pseudomonas Aeruginosa, Cyanide Accumulation and Lung Function in CF and non-CF Bronchiectasis Patients</article-title>. <source>Eur. Respir. J.</source> <volume>32</volume>, <fpage>740</fpage>&#x2013;<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00159607</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarwar</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Lundgren</surname> <given-names>B. R.</given-names>
</name>
<name>
<surname>Grassa</surname> <given-names>M. T.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M. X.</given-names>
</name>
<name>
<surname>Gribble</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Moffat</surname> <given-names>J. F.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Gcsr, A Tyrr-Like Enhancer-Binding Protein, Regulates Expression of the Glycine Cleavage System in Pseudomonas Aeruginosa PAO1</article-title>. <source>mSphere</source> <volume>1</volume> (<issue>2</issue>), <fpage>e00020</fpage>&#x2013;<lpage>e00016</lpage>. doi: <pub-id pub-id-type="doi">10.1128/mSphere.00020-16</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Clark</surname> <given-names>K. F.</given-names>
</name>
<name>
<surname>Greene</surname> <given-names>A. A.</given-names>
</name>
<name>
<surname>Reisch</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Markello</surname> <given-names>T. C.</given-names>
</name>
<name>
<surname>Gahl</surname> <given-names>W. A.</given-names>
</name>
<etal/>
</person-group>. (<year>1995</year>). <article-title>Recent Advances in the Treatment of Cystinosis</article-title>. <source>J. Inherit. Metab. Dis.</source> <volume>18</volume> (<issue>4</issue>), <fpage>387</fpage>&#x2013;<lpage>397</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00710051</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senior</surname> <given-names>N. J.</given-names>
</name>
<name>
<surname>Bagnall</surname> <given-names>M. C.</given-names>
</name>
<name>
<surname>Champion</surname> <given-names>O. L.</given-names>
</name>
<name>
<surname>Reynolds</surname> <given-names>S. E.</given-names>
</name>
<name>
<surname>La Ragione</surname> <given-names>R. M.</given-names>
</name>
<name>
<surname>Woodward</surname> <given-names>M. J.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Galleria Mellonella as an Infection Model for Campylobacter Jejuni Virulence</article-title>. <source>J. Med. Microbiol.</source> <volume>60</volume> (<issue>Pt 5</issue>), <fpage>661</fpage>&#x2013;<lpage>669</lpage>. doi: <pub-id pub-id-type="doi">10.1099/jmm.0.026658-0</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Rpon-Dependent Direct Regulation of Quorum Sensing and the Type VI Secretion System in Pseudomonas Aeruginosa PAO1</article-title>. <source>J. Bacteriol.</source> <volume>200</volume> (<issue>16</issue>), <fpage>e00205</fpage>&#x2013;<lpage>e00218</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JB.00205-18</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shrestha</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Assani</surname> <given-names>K. D.</given-names>
</name>
<name>
<surname>Rinehardt</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Albastroiu</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Shell</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Cysteamine-Mediated Clearance of Antibiotic-Resistant Pathogens in Human Cystic Fibrosis Macrophages</article-title>. <source>PloS One</source> <volume>12</volume> (<issue>10</issue>), <fpage>e0186169</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0186169</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shrestha</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Wisniewski</surname> <given-names>B.</given-names>
</name>
<name>
<surname>H&#xe4;fner</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Elie</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Meijer</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>(R)-Roscovitine and CFTR Modulators Enhance Killing of Multi-Drug Resistant Burkholderia Cenocepacia by Cystic Fibrosis Macrophages</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>21700</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-78817-x</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname> <given-names>E. E.</given-names>
</name>
<name>
<surname>Buckley</surname> <given-names>D. G.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Saenphimmachak</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Hoffman</surname> <given-names>L. R.</given-names>
</name>
<name>
<surname>D'Argenio</surname> <given-names>D. A.</given-names>
</name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Genetic Adaptation by Pseudomonas Aeruginosa to the Airways of Cystic Fibrosis Patients</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>103</volume>, <fpage>8487</fpage>&#x2013;<lpage>8492</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0602138103</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname> <given-names>P. K.</given-names>
</name>
<name>
<surname>Krohn</surname> <given-names>R. I.</given-names>
</name>
<name>
<surname>Hermanson</surname> <given-names>G. T.</given-names>
</name>
<name>
<surname>Mallia</surname> <given-names>A. K.</given-names>
</name>
<name>
<surname>Gartner</surname> <given-names>F. H.</given-names>
</name>
<name>
<surname>Provenzano</surname> <given-names>M. D.</given-names>
</name>
<etal/>
</person-group>. (<year>1985</year>). <article-title>Measurement of Protein Using Bicinchoninic Acid</article-title>. <source>Anal. Biochem.</source> <volume>150</volume> (<issue>1</issue>), <fpage>76</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0003-2697(85)90442-7</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Rowbotham</surname> <given-names>N. J.</given-names>
</name>
<name>
<surname>Charbek</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inhaled Antibiotics for Pulmonary Exacerbations in Cystic Fibrosis</article-title>. <source>Cochrane Database Syst. Rev.</source> <volume>10</volume> (<issue>10</issue>), <fpage>CD008319</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD008319.pub3</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Stiernagle</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2006</year>). <source>Maintenance of C. Elegans</source> (<publisher-name>Wormbook</publisher-name>). doi: <pub-id pub-id-type="doi">10.1895/wormbook.1.7.1</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahrioui</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Duchesne</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bouffartigues</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Rodrigues</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Maillot</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Tortuel</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Extracellular DNA Release, Quorum Sensing, and Prrf1/F2 Small Rnas are Key Players in Pseudomonas Aeruginosa Tobramycin-Enhanced Biofilm Formation</article-title>. <source>NPJ Biofilms Microbiomes</source> <volume>5</volume> (<issue>1</issue>), <fpage>15</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41522-019-0088-3</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname> <given-names>G. K.</given-names>
</name>
<name>
<surname>Goodlett</surname> <given-names>D. R.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Rules Governing Protein Identification by Mass Spectrometry</article-title>. <source>Rapid Commun. Mass Spectrom.</source> <volume>19</volume> (<issue>23</issue>), <fpage>3420</fpage>. doi: <pub-id pub-id-type="doi">10.1002/rcm.2225</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terzuoli</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Leoncini</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Pagani</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Guerranti</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Vannoni</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Ponticelli</surname> <given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>1998</year>). <article-title>Some Chemical Properties and Biological Role of Thiazolidine Compounds</article-title>. <source>Life Sci.</source> <volume>63</volume> (<issue>14</issue>), <fpage>1251</fpage>&#x2013;<lpage>1267</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0024-3205(98)00387-7</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trubiano</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Padiglione</surname> <given-names>A. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Nosocomial Infections in the Intensive Care Unit</article-title>. <source>Anaesth. Intensive Care</source> <volume>16</volume>, <fpage>598</fpage>&#x2013;<lpage>602</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mpaic.2015.09.010</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vale</surname> <given-names>P. F.</given-names>
</name>
<name>
<surname>McNally</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Doeschl-Wilson</surname> <given-names>A.</given-names>
</name>
<name>
<surname>King</surname> <given-names>K. C.</given-names>
</name>
<name>
<surname>Popat</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Domingo-Sananes</surname> <given-names>M. R.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Beyond Killing Can We Find New Ways to Manage Infection</article-title>? <source>Evol. Med. Public Health</source> <volume>2016</volume> (<issue>1</issue>), <fpage>148</fpage>&#x2013;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1093/emph/eow012</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viducic</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Murakami</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Amoh</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Ono</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Miyake</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Rpon Promotes Pseudomonas Aeruginosa Survival in the Presence of Tobramycin</article-title>. <source>Front. Microbiol.</source> <volume>8</volume>, <elocation-id>839</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2017.00839</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Brlr From Pseudomonas Aeruginosa is a Receptor for Both Cyclic Di-GMP and Pyocyanin</article-title>. <source>Nat. Commun.</source> <volume>9</volume> (<issue>1</issue>), <fpage>2563</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-05004-y</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wayne</surname> <given-names>P. A.</given-names>
</name>
<collab>Clinical and Laboratory. Standards Institute</collab>
</person-group> (<year>2015</year>). <source>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</source>, Approved Standard&#x2014;Tenth Edition. CLSI document M07-A10. <publisher-name>The Clinical and Laboratory Standards Institute (CLSI).</publisher-name>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whiteley</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>K. M.</given-names>
</name>
<name>
<surname>Greenberg</surname> <given-names>E. P.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Identification of Genes Controlled by Quorum Sensing in Pseudomonas Aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>96</volume> (<issue>24</issue>), <fpage>13904</fpage>&#x2013;<lpage>13909</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.24.13904</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organisation (WHO)</collab>
</person-group>. (<year>2017</year>). <source>Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics.</source> (<publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>). Available at: <uri xlink:href="https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf">https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf</uri> (Accessed <access-date>22 March 2021</access-date>).</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiehlmann</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Wagner</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Cramer</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Siebert</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Gudowius</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Morales</surname> <given-names>G.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Population Structure of Pseudomonas Aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>104</volume> (<issue>19</issue>), <fpage>8101</fpage>&#x2013;<lpage>8106</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0609213104</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winson</surname> <given-names>M. K.</given-names>
</name>
<name>
<surname>Camara</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Latifi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Foglino</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Chhabra</surname> <given-names>S. R.</given-names>
</name>
<name>
<surname>Daykin</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>1995</year>). <article-title>Multiple N-Acyl-L-Homoserine Lactone Signal Molecules Regulate Production of Virulence Determinants and Secondary Metabolites in Pseudomonas Aeruginosa</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>92</volume> (<issue>20</issue>), <fpage>9427</fpage>&#x2013;<lpage>9431</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.92.20.9427</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winstanley</surname> <given-names>C.</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Brockhurst</surname> <given-names>M. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Pseudomonas Aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections</article-title>. <source>Trends Microbiol.</source> <volume>24</volume> (<issue>5</issue>), <fpage>327</fpage>&#x2013;<lpage>337</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tim.2016.01.008</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Wood</surname> <given-names>W. B.</given-names>
</name>
</person-group> (<year>1988</year>). &#x201c;<article-title>Introduction to C. Elegans Biology</article-title>,&#x201d; in <source>The Nematode Caenorhabditis Elegans</source>. Ed. <person-group person-group-type="editor">
<name>
<surname>Wood</surname> <given-names>W. B.</given-names>
</name>
</person-group> (<publisher-loc>Cold Spring Harbor, NY</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory</publisher-name>), <fpage>1</fpage>&#x2013;<lpage>16</lpage>.</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Dandekar</surname> <given-names>A. A.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>A Metabolic Trade-Off Modulates Policing of Social Cheaters in Populations of Pseudomonas Aeruginosa</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <elocation-id>337</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2018.00337</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname> <given-names>R. W.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Ka</surname> <given-names>J. O.</given-names>
</name>
<name>
<surname>Krishnapillai</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Zimmermann</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Baird</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>1995</year>). <article-title>Anaerobic Activation of the Entire Denitrification Pathway in Pseudomonas Aeruginosa Requires Anr, an Analog of Fnr</article-title>. <source>J. Bacteriol.</source> <volume>177</volume> (<issue>12</issue>), <fpage>3606</fpage>&#x2013;<lpage>3609</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jb.177.12.3606-3609.1995</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yudkoff</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Nissim</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Schneider</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Segal</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>1981</year>). <article-title>Cysteamine Inhibition of [15N]-Glycine Turnover in Cystinosis and of Glycine Cleavage <italic>In Vitro</italic>
</article-title>. <source>Metab. Clin. Exp.</source> <volume>30</volume> (<issue>11</issue>), <fpage>1096</fpage>&#x2013;<lpage>1103</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0026-0495(81)90054-8</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmermann</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Reimmann</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Galimand</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Haas</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Anaerobic Growth and Cyanide Synthesis of Pseudomonas Aeruginosa Depend on Anr, a Regulatory Gene Homologous With Fnr of Escherichia Coli</article-title>. <source>Mol. Microbiol.</source> <volume>5</volume> (<issue>6</issue>), <fpage>1483</fpage>&#x2013;<lpage>1490</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2958.1991.tb00794.x</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>